

Historical Control Data
on Histological Findings in 28 days Studies
in RccHanTM: WIST, Wistar Hannover Rats

Compiled from 28 days Bioassays performed at Harlan Laboratories Ltd. Itingen/Switzerland

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Identification

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
691896	1	<input checked="" type="checkbox"/>	Juni-Juli 1998	Gavage	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	JMA
698894	2	<input checked="" type="checkbox"/>	Juli-September 1998	Gavage	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	VOO
720707	3	<input checked="" type="checkbox"/>	February-April 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
721440	4	<input checked="" type="checkbox"/>	March-April 1999	Gavage	6	7	136 - 152	110 - 131	Group	Kliba 3433	Bi-distilled water	WEK
725567	5	<input checked="" type="checkbox"/>	April-May 1999	Gavage	6	7	135 - 151	111 - 134	Group	Kliba 3433	Bi-distilled water	KHE
725264	6	<input type="checkbox"/>	May-June 1999	Gavage	6	7	125 - 161	105 - 122	Group	Kliba 3433	Bi-distilled water	KHE
741835	7	<input type="checkbox"/>	August-September 1999	Gavage	6	7	132- 179	104 - 134	Group	Kliba 3433	Bi-distilled water	KHE
737741	8	<input type="checkbox"/>	August-September 1999	Gavage	6	7	122 - 158	102 - 127	Group	Kliba 3433	Bi-distilled water	KHE
693483	9	<input checked="" type="checkbox"/>	May-July 1998	Gavage	6	7	135 - 172	108 - 143	Group	Kliba 3433	Bi-distilled water	KHE
706397	10	<input checked="" type="checkbox"/>	September-November 1998	Gavage	6	7	129 - 176	122 - 147	Group	Kliba 3433	Bi-distilled water	KHE
706882	11	<input checked="" type="checkbox"/>	October-Novemder 1998	Gavage	6	7	115 - 144	94 - 127	Group	Kliba 3433	Bi-distilled water	WEK
707591	12	<input checked="" type="checkbox"/>	October-November 1998	Gavage	6	7	119 - 142	97 - 121	Group	Kliba 3433	Bi-distilled water	WEK
702033	13	<input checked="" type="checkbox"/>	September-November 1998	Gavage	6	7	130 - 172	113 - 130	Group	Kliba 3433	Bi-distilled water	WEK
731305	14	<input checked="" type="checkbox"/>	June-July 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
730023	15	<input checked="" type="checkbox"/>	April-June 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	KHE
746910	16	<input type="checkbox"/>	October-November 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
724511	17	<input type="checkbox"/>	May-June 1999	Gavage	6	7	139 - 161	107 - 131	Group	Kliba 3433	Polyethylene glycol (PEG) 300	KHE
716455	18	<input checked="" type="checkbox"/>	February-April 1999	Gavage	6	7	124 - 136	116 - 125	Group	Kliba 3433	PEG 300	KHE
723082	19	<input type="checkbox"/>	May-June 1999	Gavage	6	7	135 - 151	116 - 127	Group	Kliba 3433	PEG 300	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
714306	20	<input checked="" type="checkbox"/>	December 1998-February 1999	Gavage	6	7	135 - 156	117 - 132	Group	Kliba 3433	PEG 300	WEK
741508	21	<input type="checkbox"/>	August-September 1999	Gavage	6	7	125 - 159	101 - 132	Group	Kliba 3433	PEG 300	KHE
727323	22	<input checked="" type="checkbox"/>	April-June 1999	Gavage	6	7	113 - 145	104 - 131	Group	Kliba 3433	PEG 300	KHE
742252	23	<input checked="" type="checkbox"/>	August-October 1999	Gavage	6	7	120 - 157	96 - 144	Group	Kliba 3433	PEG 300	WEK
747966	24	<input type="checkbox"/>	December 1999-January 2000	Gavage	6	7	129 - 156	103 - 133	Group	Kliba 3433	PEG 300	KHE
747156	25	<input type="checkbox"/>	November-December 1999	Gavage	6	7	149 - 185	122 - 145	Group	Kliba 3433	PEG 300	WEK
746730	26	<input checked="" type="checkbox"/>	October-December 1999	Gavage	6	7	124 - 169	108 - 137	Group	Kliba 3433	PEG 300	WEK
744535	27	<input type="checkbox"/>	November 1999-January 2000	Gavage	6	7	124 - 160	111 - 133	Group	Kliba 3433	PEG 300	WEK
727018	28	<input type="checkbox"/>	April-May 1999	Gavage	6	7	134 - 147	115 - 128	Group	Kliba 3433	PEG 300	KHE
700075	29	<input type="checkbox"/>	August-September 1998	Gavage	6	7	126 - 172	109 - 135	Group	Kliba 3433	PEG 300	WEK
720257	30	<input type="checkbox"/>	February-March 1999	Gavage	6	7	137 - 150	112 - 124	Group	Kliba 3433	PEG 300	KHE
726074	31	<input checked="" type="checkbox"/>	April-May 1999	Gavage	6	7	135 - 153	115 - 133	Group	Kliba 3433	PEG 300	WEK
710414	32	<input type="checkbox"/>	January-February 1999	Gavage	6	7	179 - 196	118 - 129	Group	Kliba 3433	PEG 300	KHE
712135	33	<input checked="" type="checkbox"/>	December 1998-January 1999	Gavage	6	7	140 - 157	111 - 132	Group	Kliba 3433	PEG 300	WIL
743512	34	<input checked="" type="checkbox"/>	September-November 1999	Gavage	6	7	144 - 174	112 - 148	Group	Kliba 3433	PEG 300	MIP
648990	35	<input checked="" type="checkbox"/>	February-April 1997	Gavage	6	7	127 - 165	109 - 145	Group	Kliba 343	Bi-distilled water	WIL
636456	36	<input checked="" type="checkbox"/>	October-November 1996	Gavage	6	7	130 - 173	112 - 146	Group	Kliba 343	PEG 400	WEK
642240	37	<input type="checkbox"/>	December 1996-January 1997	Gavage	6	7	132 - 173	127 - 145	Group	Kliba 343	Bi-distilled water	WIL
656572	38	<input type="checkbox"/>	June-July 1997	Gavage	6	7	135 - 155	109 - 129	Group	Kliba 343	PEG 400	WIL
652601	39	<input checked="" type="checkbox"/>	April-May 1997	Gavage	6	7	133 - 151	109 - 131	Group	Kliba 343	Bi-distilled water	WEK
637740	40	<input checked="" type="checkbox"/>	November-December 1996	Gavage	6	7	127 - 172	110 - 146	Group	Kliba 343	Bi-distilled water	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
644365	41	<input checked="" type="checkbox"/>	April-May 1997	Gavage	6	7	132 - 154	107 - 129	Group	Kliba 343	0.6 % Carboxymethylcellulose (CMC)	JMA
650744	42	<input type="checkbox"/>	June-July 1997	Gavage	6	7	133 - 159	107 - 130	Group	Kliba 343	Sesame oil	WEK
643961	43	<input checked="" type="checkbox"/>	March-April 1997	Gavage	4	14	118 - 140	87 - 109	Group	Kliba 343	Bi-distilled water	WIL
647651	44	<input checked="" type="checkbox"/>	February-April 1997	Gavage	6	7	124 - 158	102 - 136	Group	Kliba 343	Bi-distilled water	WIL
660510	45	<input type="checkbox"/>	July-August 1997	Gavage	6	7	127 - 157	110 - 133	Group	Kliba 343	Bi-distilled water	HJC
654917	46	<input type="checkbox"/>	April-June 1997	Gavage	6	8	136 - 155	112 - 130	Group	Kliba 343	0.5 % CMC in Bi-distilled water	WEK
C29568	47	<input checked="" type="checkbox"/>	February - March 2009	Inhalation	7 to 9	5	mean±20%	mean±20%	Group	Kliba 3433	Placebo	HJC
646154	48	<input type="checkbox"/>	March-April 1997	Intravenous	7	7	171 - 197	133 - 154	Group	Kliba 343	Physiological saline (0.9% NaCl)	WIL
657505	49	<input type="checkbox"/>	April-May 1997	Gavage	6	7	137 - 153	106 - 130	Group	Kliba 343	PEG 400	WEK
654287	50	<input checked="" type="checkbox"/>	April-June 1997	Gavage	6	7	133 - 154	110 - 128	Group	Kliba 343	Bi-distilled water	WEK
653264	51	<input checked="" type="checkbox"/>	April-June 1997	Gavage	6	6	132 - 155	109 - 129	Group	Kliba 343	Bi-distilled water	WEK
644253	52	<input checked="" type="checkbox"/>	December 1996-February 1997	Gavage	6	7	135 - 176	103 - 143	Group	Kliba 343	Bi-distilled water	WIL
639731	53	<input checked="" type="checkbox"/>	December 1996-January 1997	Gavage	6	7	127 - 176	98 - 130	Group	Kliba 343	Bi-distilled water	WIL
623777	54	<input checked="" type="checkbox"/>	May-June 1996	Gavage	6	7	127 - 170	111 - 142	Group	Kliba 343	Bi-distilled water / PEG 400	WIL
617556	55	<input checked="" type="checkbox"/>	February-April 1996	Gavage	6	7	149 - 173	120 - 148	Group	Kliba 343	Bi-distilled water	WIL
629234	56	<input checked="" type="checkbox"/>	August-September 1996	Gavage	6	7	113 - 160	101 - 140	Group	Kliba 343	Bi-distilled water	WIL
632182	57	<input checked="" type="checkbox"/>	August-October 1996	Gavage	6	7	125 - 181	98 - 129	Group	Kliba 343	Bi-distilled water	WIL
632722	58	<input checked="" type="checkbox"/>	September-October 1996	Gavage	6	7	121 - 157	111 - 142	Group	Kliba 343	Corn oil	WIL
603527	59	<input checked="" type="checkbox"/>	July-September 1995	Gavage	6	7	136 - 246	117 - 134	Individually	Kliba 343	Bi-distilled water	WIL
601378	60	<input checked="" type="checkbox"/>	August-October 1995	Gavage	6	7	137 - 152	114 - 126	Individually	Kliba 343	Bi-distilled water	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
B85318	61	<input checked="" type="checkbox"/>	October - November 2008	Inhalation	♂:6-8♀:8-10	5	mean±20%	mean±20%	Groups	Kliba Nafag 3433	Formulation buffer of DA-3201	HJC
620662	62	<input type="checkbox"/>	June-July 1996	Gavage	6	7	125 - 167	105 - 144	Groups	Kliba 343	Corn oil	WIL
C36476	63	<input checked="" type="checkbox"/>	February - March 2009	Subcutaneous	6	7	150 (±20%)	125 (±20%)	Groups	Kliba Nafag 3433	4.5% Mannitol in water	PAV
609210	64	<input type="checkbox"/>	January-March 1996	Gavage	6	7	136 - 160	119 - 137	Individually	Kliba 343	Bi-distilled water	WEK
618625	65	<input checked="" type="checkbox"/>	April-May 1996	Gavage	6	7	150 - 176	106 - 127	Groups	Kliba 343	Corn oil	WEK
621551	66	<input checked="" type="checkbox"/>	May-June 1996	Gavage	6	7	133 - 171	116 - 141	Groups	Kliba 343	Bi-distilled water	WEK
621821	67	<input checked="" type="checkbox"/>	May-June 1996	Gavage	6	7	139 - 174	115 - 147	Groups	Kliba 343	PEG 400	WIL
643083	68	<input checked="" type="checkbox"/>	December1996-January 1997	Gavage	6	7	126 - 172	99 - 145	Groups	Kliba 343	Bi-distilled water	WIL
846238	69	<input type="checkbox"/>	October 2002 – November 2002	Gavage	6	7	134 - 158	111 - 130	Groups	Kliba 343	Corn oil	KOD
841496	70	<input checked="" type="checkbox"/>	February 2002 – April 2002	Gavage	5	16	110 (±20%)	100 (±20%)	Groups	NAFAG 8900	Bi-distilled water	ABR
762658	71	<input type="checkbox"/>	March – April 2000	Feeding	5	6	110 (±20%)	95 (±20%)	Groups	Kliba 3433	Diet	WEK
841039	72	<input checked="" type="checkbox"/>	January – February 2002	Gavage	6	6	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	MIP
825467	73	<input type="checkbox"/>	October – November 2002	Inhalation	♂:6-8♀:8-10	5	180 - 200	180 - 200	Groups	Kliba 3433	NaCl, 0.9% (0.9% w/v sodium chloride solution)	WEK
843046	74	<input checked="" type="checkbox"/>	May – June 2002	Gavage	5	15	110 (±20%)	110 (±20%)	Groups	NAFAG 8900	0.5% CMC in 0.1% (w/v) aqueous polysorbate 80	ABR
842083	75	<input checked="" type="checkbox"/>	April – May 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	NED
842083	76	<input checked="" type="checkbox"/>	March – April 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	NED
845763	77	<input type="checkbox"/>	December 2002 - January 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Corn oil	WEK
844408	78	<input type="checkbox"/>	July – August 2002	Gavage	6	5	No males	125 (±20%)	Groups	Kliba 3433	Group 01: CMC Group 02: Cremophor	KHE
849144	79	<input type="checkbox"/>	Juni – Juli 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Ultrapure water	SPH
841855	80	<input checked="" type="checkbox"/>	March – April 2002	Inhalation	♂ : 6 - 8 ♀ : 8 - 10	14	180-200	180-200	Groups	Kliba 3433	Air control	WEK
844400	81	<input checked="" type="checkbox"/>	July – August 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	Hydroxyethylcellulose zur Synthese 0,5%ig, Merck S22341743	JAG

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
844782	82	<input type="checkbox"/>	December 2002 - January 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	PEG 300	NED
841798	83	<input type="checkbox"/>	March - April 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	PEG 300	NED
830351	84	<input checked="" type="checkbox"/>	January - February 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	PEG 300	TOX
829067	85	<input checked="" type="checkbox"/>	October - November 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	0.5% Methocel MC	JAG
844804	86	<input checked="" type="checkbox"/>	July - August 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	Methocel MC 0.25% in water	WEK
846939	87	<input checked="" type="checkbox"/>	January - February 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	Bi-distilled water	NED
841557	88	<input checked="" type="checkbox"/>	February - March 2002	Gavage	6	6	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Corn oil	PSC
820315	89	<input type="checkbox"/>	July – August 2001	Gavage	12	7	220 (±20%)	250 (±20%)	Groups	Kliba 3433	4% Methocel E 15 with 2-3 drops of Med Antifoam C/200ml	WEK
843756	90	<input checked="" type="checkbox"/>	July - August 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	JAG
845279	91	<input checked="" type="checkbox"/>	October - November 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	WEK
845307	92	<input checked="" type="checkbox"/>	October - November 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	NED
843129	93	<input checked="" type="checkbox"/>	March - April 2002	Intravenous	6	7	200 (±20%)	150 (±20%)	Individually	Kliba 3433	Group 01: PBS buffer Group 02: PC-Liposomes (B)	NED
845823	94	<input checked="" type="checkbox"/>	October - November 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	KOD
845044	95	<input checked="" type="checkbox"/>	September - Oktober 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	GKR
841255	96	<input type="checkbox"/>	February - March 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	GKR
844990	97	<input type="checkbox"/>	August - September 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	0.5% aqueous solution of CMC	NED
844693	98	<input type="checkbox"/>	August - September 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	1,2-propylene glycol	NED
842520	99	<input checked="" type="checkbox"/>	March - April 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	GKR
842614	100	<input checked="" type="checkbox"/>	April - May 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	NED
844256	101	<input checked="" type="checkbox"/>	July - August 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	JAG
842658	102	<input checked="" type="checkbox"/>	April - May 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	ABR

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
841276	103	<input checked="" type="checkbox"/>	January - February 2002	Gavage	6	7	125-158 (mean 142)	112-132 (mean 121)	Groups	Kliba 3433	PEG 300	NED
841901	104	<input checked="" type="checkbox"/>	February - March 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	HJC
845437	105	<input checked="" type="checkbox"/>	November-December 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	KOD
844691	106	<input type="checkbox"/>	August - September 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Tylose CB 30000P2 (in 0.5% aqueous solution)	MIP
845375	107	<input checked="" type="checkbox"/>	October - November 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	AKR
841315	108	<input type="checkbox"/>	January - February 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	MIP
844692	109	<input type="checkbox"/>	August - September 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	MIP
841313	110	<input checked="" type="checkbox"/>	January - February 2002	Gavage	6	5	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	GKR
844149	111	<input checked="" type="checkbox"/>	Juni – Juli 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	MIP
843219	112	<input checked="" type="checkbox"/>	May – June 2002	Gavage	5	13	110 (±20%)	100 (±20%)	Groups	Kliba 3433	CMC 0.5% (w/v)/ polysorbate (TWEEN) 80 0.1% (w/v)	ABR
826661	113	<input checked="" type="checkbox"/>	January - February 2002	Inhalation	♂ : 6 - 8 ♀ : 8 - 10	14	180-200	180-200	Groups	Kliba 3433	Pharmatose 325 MESH 90%	WEK
843520	114	<input checked="" type="checkbox"/>	July - August 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	GKR
842880	115	<input checked="" type="checkbox"/>	April - May 2002	Gavage	8	7	230 (±20%)	170 (±20%)	Groups	Kliba 3433	Thixotrope	LAN
785103	116	<input checked="" type="checkbox"/>	December 2000 - January 2001	Gavage	6	7	121 - 172	98 - 146	Groups	Kliba 3433	Bi-distilled water	WEK
814858	117	<input type="checkbox"/>	May 2001 - June 2002	Dermal	6	7	91 - 128	89 - 118	Group	Kliba 3433	1% LAS 33774	WEK
832781	118	<input type="checkbox"/>	October - December 2001	Gavage	6	7	119 - 155	108 - 132	Group	Kliba 3433	PEG 300	NED
783180	119	<input type="checkbox"/>	September 2000 - August 2001	Dermal	♂ : 9 ♀ : : 14	7	193 - 209	176 - 214	Group	Kliba 3433	FK117 GEL	WEK
793394	120	<input checked="" type="checkbox"/>	November 2000 - Januar 2001	Gavage	6	7	126 - 160	111 - 172	Groups	Kliba 3433	Bi-distilled water	WEK
766405	121	<input checked="" type="checkbox"/>	May- June 2000	Gavage	6	6	115 - 161	94 - 134	Group	Kliba 3433	Bi-distilled water	WEK
780118	122	<input checked="" type="checkbox"/>	April- August 2001	Inhalation	♂ : 6 - 8 ♀ : 10 - 12	14	180 -	200	Group	Kliba 3433	DEXBUD/HFA	WEK
774270	123	<input type="checkbox"/>	June - August 2000	Gavage	6	7	134 - 174	111 - 141	Group	Kliba 3433	Bi-distilled water	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
707771	124	<input checked="" type="checkbox"/>	January 1999-April 2001	Inhalation	♂ : 8 - 11 ♀ : 10-13	5 ; 14	179 - 241	179 - 211	Group	Kliba 3433	HFA	WEK
763582	125	<input type="checkbox"/>	April - May 2000	Gavage	6	7	120 - 160	106 - 141	Group	Kliba 3433	Bi-distilled water	WEK
726557	126	<input type="checkbox"/>	April - June 1999	Gavage	5	6	111 - 134	93 - 115	Group	Kliba 3433	LAS 32928	WEK
829067	127	<input checked="" type="checkbox"/>	October 2002 - July 2003	Gavage	6	7	127 - 162	110 - 131	Group	Kliba 3433	0,5% aqueous Methocel solution	JAG
822510	128	<input type="checkbox"/>	August - December 2001	Inhalation	♂ : 7 - 9 ♀ : 10 - 12	12	±20%	of the maen weight	Group	Kliba 3433	1 dose group: riboflavin formulation 3 dose group: AWD 12-281 formulation	WEK
789041	129	<input type="checkbox"/>	June - August 2001	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Peanut oil (desiccated)	CMA
821316	130	<input type="checkbox"/>	August - October 2001	Gavage	6	7	132 - 157	114 - 131	Group	Kliba 3433	PEG 300	KOD
B52323	131	<input type="checkbox"/>	September- Novembre 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	BDK
B26201	132	<input type="checkbox"/>	May- July 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	KHE
B10440	133	<input checked="" type="checkbox"/>	March- April 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	BDK
851521	134	<input checked="" type="checkbox"/>	April - May 2004	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	0,5% Methylcellulose	KHE
851858	135	<input checked="" type="checkbox"/>	January - Febuary 2004	Gavage	6	6	150 (±20%)	125 (±20%)	Group	Kliba 3433	SSV	MAM
A92608	136	<input checked="" type="checkbox"/>	September - October 2006	Gavage	7	7	175 (±20%)	140 (±20%)	Group	Kliba 3433	Aqua bidest	WEK
C16823	137	<input type="checkbox"/>	December 2008 - January 2009	Intravenous	7	7-8	190(±20%)	150(±20%)	Group	Kliba 3433	PBS	KOD
852202	138	<input checked="" type="checkbox"/>	Febuary - March 2004	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	WLA
852372	139	<input checked="" type="checkbox"/>	February - March 2004	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	PAV
853022	140	<input type="checkbox"/>	March - April 2004	Feeding	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diet	WLA
855727	141	<input checked="" type="checkbox"/>	January - March 2005	Intravenous	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	N1509 Injectable NanoCrystal	PAV
858100	142	<input checked="" type="checkbox"/>	January - Febuary 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	NED
858304	143	<input checked="" type="checkbox"/>	July - September 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	0.5% Carboxymethyl Cellulose	MAM
858351	144	<input checked="" type="checkbox"/>	May - July 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Sterole water for injection	NED

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
858417	145	<input type="checkbox"/>	February - March 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	JAG
858453	146	<input checked="" type="checkbox"/>	April - June 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	NED
858591	147	<input type="checkbox"/>	March - April 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	NED
858754	148	<input checked="" type="checkbox"/>	March - May 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	VOO
858852	149	<input checked="" type="checkbox"/>	March - April 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	NIH31- 2050	0.5% Carboxymethyl Cellulose	NED
859022	150	<input checked="" type="checkbox"/>	May - June 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	PAV
859141	151	<input checked="" type="checkbox"/>	June - July 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Corn Oil	ROL
859248	152	<input checked="" type="checkbox"/>	March - April 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Physiological saline (0.9% NaCl)	KHE
859361	153	<input checked="" type="checkbox"/>	May - June 2005	Gavage	6	8	150 (±20%)	125 (±20%)	Group	Kliba 3434	PEG 300	ROL
A00821	154	<input type="checkbox"/>	July - August 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	PEG 300	ROL
A02586	155	<input checked="" type="checkbox"/>	May - June 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Corn Oil	JAG
A05141	156	<input checked="" type="checkbox"/>	May - June 2005	Gavage	8	7	190 (±10%)	140 (±10%)	Group	Kliba 3434	Na-Carboxymethylcellulose (0.5%)	KHE
A06513	157	<input type="checkbox"/>	July - August 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Purified water	PAV
A07705	158	<input checked="" type="checkbox"/>	July - August 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Bi-distilled water	PAV
A11643	159	<input checked="" type="checkbox"/>	August - September 2005	Intravenous	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	0.9% physiological saline	PAV
A11834	160	<input type="checkbox"/>	June - July 2005	Feeding	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Diet	PAV
A13781	161	<input checked="" type="checkbox"/>	August - September 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Corn Oil	JAG
A14668	162	<input checked="" type="checkbox"/>	July - August 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	KHE
A15131	163	<input type="checkbox"/>	July - August 2005	Gavage	6	7	150 - 180	125 - 150	Group	Kliba 3433	Carboxymethylcellulose	SPH
A16198	164	<input type="checkbox"/>	August - September 2005	Feeding	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diet	ROL
A17728	165	<input type="checkbox"/>	September - November 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	SPH

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
A17908	166	<input type="checkbox"/>	September - October 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	0.4% aqueous solution of ascorbic acid	ROL
A20351	167	<input checked="" type="checkbox"/>	September - October 2005	Feeding	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diet	PAV
A20698	168	<input type="checkbox"/>	August - September 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	MAM
A21407	169	<input checked="" type="checkbox"/>	August - September 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	ROL
A21846	170	<input checked="" type="checkbox"/>	October - November 2005	Intravenous	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	0.9% physiological saline	PAV
A27246	171	<input type="checkbox"/>	October - November 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	ROL
A28765	172	<input type="checkbox"/>	October - November 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	ROL
A36742	173	<input type="checkbox"/>	December - January 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	BDK
A41196	174	<input checked="" type="checkbox"/>	December 2005 - January 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	VOO
A09448	175	<input checked="" type="checkbox"/>	May - June 2006	Gavage	6	10	150 (±20%)	125 (±20%)	Group	Kliba 3433	Methyl Cellulose	WEK
A43097	176	<input checked="" type="checkbox"/>	February - March 2006	Gavage	6	7	134.2-164.9	115.5-135.7	Group	Kliba 3433	1% Carboxymethylcellulose	PAV
A43626	177	<input type="checkbox"/>	January - February 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	BDK
A44717	178	<input checked="" type="checkbox"/>	March - April 2006	Semiocclusive		6	200 - 300	200 - 300	Group	Kliba 3433	CMC	PAV
A44886	179	<input type="checkbox"/>	July - August 2006	Injection & Gavage	3	6	approx. 40	approx. 30	Group	Kliba 3433	1% Tween 80 in bidistilled water	WEK
A45336	180	<input checked="" type="checkbox"/>	January - February 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	PAV
A46620	181	<input checked="" type="checkbox"/>	May - June 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	MAM
A47632	182	<input checked="" type="checkbox"/>	January - February 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	ROL
A50477	183	<input checked="" type="checkbox"/>	March - April 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	PAV
A53842	184	<input checked="" type="checkbox"/>	April - May 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	PAV
A54134	185	<input type="checkbox"/>	March - April 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	BDK
A54347	186	<input type="checkbox"/>	March - April 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
A58408	187	<input type="checkbox"/>	July - August 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	TAT
A62594	188	<input checked="" type="checkbox"/>	April - May 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	HJC
A62943	189	<input checked="" type="checkbox"/>	July - August 2006	Subcutaneous	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Tween 80; Carboxymethylcellulose; Benzyl alcohol; 0.9% physiological saline	PAV
A65081	190	<input checked="" type="checkbox"/>	July - August 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	JAG
A70086	191	<input type="checkbox"/>	June - July 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	MAM
A70222	192	<input checked="" type="checkbox"/>	May - June 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	PAV
A71324	193	<input type="checkbox"/>	April - May 2006	Gavage	6	7	151 (±20%)	/	Group	Kliba 3433	Purified water	KHE
A73708	194	<input checked="" type="checkbox"/>	July - August 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	KHE
A73991	195	<input checked="" type="checkbox"/>	June - July 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	0.5% Carboxymethylcellulose	JAG
A74518	196	<input type="checkbox"/>	May - June 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	BDK
A74970	197	<input checked="" type="checkbox"/>	July - August 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	PAV
A80932	198	<input type="checkbox"/>	August - October 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	PAV
A85915	199	<input type="checkbox"/>	September - October 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	KHE
A89640	200	<input type="checkbox"/>	September - October 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	ROL
A90303	201	<input checked="" type="checkbox"/>	October - November 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	PAV
A93104	202	<input checked="" type="checkbox"/>	October - November 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Methylcellulose; 0.5% in water; Polysorbate 80 (Tween 80)	PAV
A93734	203	<input checked="" type="checkbox"/>	December 2006 - January 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	BDK
A96467	204	<input checked="" type="checkbox"/>	October - November 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	BDK
A98662	205	<input type="checkbox"/>	October - November 2006	Gavage	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	HJC
B04882	206	<input type="checkbox"/>	December 2006 - January 2007	Semiocclusive	♂ : 7 - 9 ♀ : 10 - 12	7	180 - 220 (±20%)	181 - 220 (±20%)	Group	Kliba 3433	Ethanol puriss	KHE
B05512	207	<input checked="" type="checkbox"/>	December 2006 - January 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	KHE

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
B08144	208	<input type="checkbox"/>	December 2006 - January 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Hydroxypropylmethylcellulose 0.2%	HJC
B08008	209	<input checked="" type="checkbox"/>	February - March 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Labrasol, Cremophor RH 40, Labrafac Lipophil WL 1349, Plurol Oleique CC	HJC
B09808	210	<input type="checkbox"/>	March - April 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	PAV
B12958	211	<input checked="" type="checkbox"/>	February - March 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	TAT
B18966	212	<input type="checkbox"/>	February - March 2007	Feeding	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Diet	BDK
B19800	213	<input checked="" type="checkbox"/>	May - June 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	TAT
B21598	214	<input type="checkbox"/>	March - April 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	ROL
B24434	215	<input type="checkbox"/>	June - July 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	BDK
B25874	216	<input type="checkbox"/>	May - June 2007	Feeding	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diet	SPH
B26572	217	<input type="checkbox"/>	May - June 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Bi-distilled water	BDK
B27494	218	<input type="checkbox"/>	August - September 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Corn Oil	IHI
B31972	219	<input checked="" type="checkbox"/>	August - September 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	BDK
B32422	220	<input checked="" type="checkbox"/>	May - June 2007	Feeding	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Diet	KHE
858959	221	<input type="checkbox"/>	March - April 2005	Gavage	6	6	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	VOO
B33063	222	<input type="checkbox"/>	August - September 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Corn Oil	TAT
B34481	223	<input checked="" type="checkbox"/>	August - September 2007	Bolus intravenous	6	7	150 (±20%)	/	Group	Kliba 3433	Bi-distilled water	TAT
B25234	224	<input checked="" type="checkbox"/>	July - August 2007	Subcutaneous	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diluent for Polysialylated Erythropoietin	HJC
B43525	225	<input type="checkbox"/>	September - October 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Bi-distilled water	BDK
C19984	226	<input checked="" type="checkbox"/>	November - December 2008	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Methylcellulose	KRG
763110	227	<input type="checkbox"/>	April - May 2000	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	WEK
770567	228	<input checked="" type="checkbox"/>	May - June 2000	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
749575	229	<input checked="" type="checkbox"/>	October - November 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	WEK
794924	230	<input checked="" type="checkbox"/>	28. Dec. 2000 - 22.Febr. 2001	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
902676	231	<input type="checkbox"/>	30. Apr.1998 - 4 Jun. 1998	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	WEK
849570	232	<input checked="" type="checkbox"/>	28. Jul. - 31. Aug. 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Water	WEK
792000	233	<input type="checkbox"/>	01. Nov. - 13 Dec. 2000	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
B65125	234	<input checked="" type="checkbox"/>	December 2007 - Januar 2008	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Corn Oil	KOD
B53403	235	<input checked="" type="checkbox"/>	October - November 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	TAT
B49184	236	<input checked="" type="checkbox"/>	December 2007 - Januar 2008	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	Refined Heavy Parafinic Diluent Mineral Oil	TAT
848428	237	<input checked="" type="checkbox"/>	May - June 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	NED
B46528	238	<input checked="" type="checkbox"/>	October - November 2007	Feeding	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Diet	BDK
B55776	239	<input checked="" type="checkbox"/>	October - November 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	BDK
B57047	240	<input checked="" type="checkbox"/>	October - November 2008	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	BDK
B61648	241	<input checked="" type="checkbox"/>	October - November 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	IHI
B62043	242	<input checked="" type="checkbox"/>	December 2007 - Januar 2008	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Purified water	IHI
B65485	243	<input type="checkbox"/>	November - December 2007	Semiocclusive	7	4	170 (±20%)	140 (±20%)	Group	Kliba 3433	0.5% (w/v) Carboxymethylcellulose in 0.1% (w/v) aqueous polysorbate 80	TAT
B68872	244	<input checked="" type="checkbox"/>	December 2007 - Januar 2008	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Sesam Oil	PAV
B33390	245	<input type="checkbox"/>	April - May 2008	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	Corn oil	HJC
B57352	246	<input type="checkbox"/>	January - February 2008	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	0.5% aqueous solution of carboxymethyl- cellulose and 0.1% Tween 80	WEK
B63450	247	<input type="checkbox"/>	January - February 2008	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	PEG 300	ROL
B74430	248	<input checked="" type="checkbox"/>	August - September 2008	1-hour infusion	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Sterile saline (0.9% w/v NaCl)	PIAL
B75958	249	<input type="checkbox"/>	March - April 2008	Subcutaneous	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	NTS with polyethylene (HDPE)	IHI

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
B83182	250	<input type="checkbox"/>	January - February 2008	Semiocclusive	♂ : 10 - 12 ♀ : 7 - 9	7	180 - 220 (±20%)	181 - 220 (±20%)	Group	Kliba 3433	mixture of 70% Ethanol and 30% purified water (v/v)	IHI
B85364	251	<input checked="" type="checkbox"/>	May - June 2009	Gavage	7	6	190 (±20%)	150 (±20%)	Group	Kliba 3433	Corn Oil	TAT
C35431	252	<input type="checkbox"/>	January - February 2009	Gavage	6	4	200 (±20%)	140 (±20%)	Group	Kliba 3433	0.5% CMC	PAV
B88334	253	<input checked="" type="checkbox"/>	June - July 2008	Semiocclusive	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	Colourless, opaque ointment formulation 70:30 White Soft Paraffin: Miglyol 812.	HJC
B97233	254	<input checked="" type="checkbox"/>	August - September 2008	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	SN11 formulation	KHE
C02215	255	<input type="checkbox"/>	August - September 2008	Gavage	6	8	150 (±20%)	125 (±20%)	Group	Kliba 3433	Lc15-0444 Tartrate	PAV
C09274	256	<input type="checkbox"/>	December 2008 - Januar 2009	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Corn Oil	IHI
C12301	257	<input checked="" type="checkbox"/>	December 2008 - Januar 2009	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	PEG 300	HJC
C21075	258	<input type="checkbox"/>	December 2008 - Januar 2009	Semiocclusive	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Bi-distilled water	KHE
C26418	259	<input checked="" type="checkbox"/>	December 2008 - Januar 2009	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	PEG 300	TAT
844476	260	<input type="checkbox"/>	June - July 2002	Gavage	6	8	150 (±20%)	125 (±20%)	Group	Kliba 3433	0.2% HPMC	WEK
605711	261	<input type="checkbox"/>	October - November 1997	Intravenous	7	4	190 (±20%)	145 (±20%)	Group	Kliba 3433	Physiological saline (0.9% NaCl)	WEK
605722	262	<input type="checkbox"/>	December 2007 - Januar 2008	Gavage	4	7	70 (±20%)	65 (±20%)	Group	Kliba 3433	Physiological saline (0.9% NaCl)	WEK
843550	263	<input type="checkbox"/>	December 1997 - Januar 1998	Inhalation	♂ : 6 - 8 ♀ : 8 - 10	14	180 - 200	181 - 200	Group	Kliba 3433	Lactose	JAG
733050	264	<input type="checkbox"/>	September - October 1999	Gavage	4	7	70 (±20%)	65 (±20%)	Group	Kliba 3433	Physiological saline (0.9% NaCl)	RON
761782	265	<input type="checkbox"/>	August - September 2000	Gavage	5	7	120 (±20%)	100 (±20%)	Group	Kliba 3433	Physiological saline (0.9% NaCl)	WEK
707242	266	<input type="checkbox"/>	February - March 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
847755	267	<input checked="" type="checkbox"/>	March - April 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	SPH
817165	268	<input type="checkbox"/>	August - September 2001	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	WEK
811732	269	<input type="checkbox"/>	April - May 2001	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
846594	270	<input type="checkbox"/>	January - February 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
847074	271	<input type="checkbox"/>	January - February 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
695913	272	<input type="checkbox"/>	March-April 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
386921	273	<input checked="" type="checkbox"/>	February - March 1995	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
846770	274	<input checked="" type="checkbox"/>	March-April 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	BBA
847835	275	<input checked="" type="checkbox"/>	February - March 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
364476	276	<input type="checkbox"/>	February - March 1994	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	WEK
807581	277	<input checked="" type="checkbox"/>	May - June 2001	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	KOD
818403	278	<input type="checkbox"/>	August - September 2001	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	WEK
677441	279	<input type="checkbox"/>	September - October 1999	Inhalation	♂ : 8-10 ♀ : 10-12	7	180 - 200	180 - 200	Group	Kliba 3433	HFA Placebo Formulation in Metered Dose Inhalers (MDI)	WEK
697781	280	<input checked="" type="checkbox"/>	July - August 1999	Inhalation	♂ : 6-8 ♀ : 10 12	7	180 - 200	180 - 200	Group	Kliba 3433	Vehicle of Budesonide unit dose	WEK
B64710	281	<input checked="" type="checkbox"/>	October - November 2007	Infusion	7	5	300(±20%)		Group	Kliba 3433	5% Glucose solution	WEK
298866	282	<input type="checkbox"/>	June - July 1991	Gavage	6	7	180 (±20%)	160 (±20%)	Group	Kliba 3433	Polyethylene glycol, PEG 400	WEK
337476	283	<input checked="" type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
346577	284	<input checked="" type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
369808	285	<input type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
375322	286	<input checked="" type="checkbox"/>	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Bi-distilled water	WEK
382588	287	<input checked="" type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Corn Oil	WEK
C31537	288	<input checked="" type="checkbox"/>	January - March 2009	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Corn Oil	WEK
391296	289	<input type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Bi-distilled water	WEK
395820	290	<input checked="" type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Polyethylene glycol, PEG 400	WEK
605024	291	<input checked="" type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Bi-distilled water	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
650845	292	<input type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
652601	293	<input checked="" type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Bi-distilled water	WEK
666797	294	<input checked="" type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Bi-distilled water	WEK
733050	295	<input type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Physiological saline (0.9% NaCl)	WEK
733882	296	<input checked="" type="checkbox"/>	n.d.	Inhalation	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
746223	297	<input checked="" type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
761782	298	<input type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
773010	299	<input checked="" type="checkbox"/>	n.d.	Inhalation	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
780772	300	<input type="checkbox"/>	n.d.	Inhalation	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
B68872	301	<input checked="" type="checkbox"/>	Dec.2007 - Jan. 2008	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Clopidogrel besylate	PAV
C32123	302	<input checked="" type="checkbox"/>	Mar 2009-May 2009	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	Polyethylene glycol, PEG 300	TAT
C00090	303	<input checked="" type="checkbox"/>	Nov. 2008 - Dec. 2008	Inhalation	8	5	n. d.	n. d.	Group	Kliba 3433	Air	KOD
C21525	304	<input type="checkbox"/>	Jan. 2009 - Feb. 2009	Subcutaneous	7	7	190 (±20%)	150 (±20%)	Individually	Kliba 3433	Physiological saline (0.9% NaCl)	IHI
C44982	305	<input type="checkbox"/>	July 2009 - November 2009	Gavage	11	n.d.	275 - 325	180 - 220	Individually	Kliba 3433	PEG 300	PAC
C64040	306	<input type="checkbox"/>	October 2009 - February 2010	Feeding	7	8	190 (±20%)	only Male	Group	Teklad 2014	Diet	WEK
C72048	307	<input type="checkbox"/>	November 2009 - February 2010	Dermal	7	5	170 (±20%)	140 (±20%)	Individually	Kliba 3433	0.5% CMC	PAC
B31713	308	<input type="checkbox"/>	April 2007 - July 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	0.5% Methylcellulose	KRG
C55951	309	<input type="checkbox"/>	October 2009 - January 2010	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	Bi-distilled water	HJC
B77275	310	<input type="checkbox"/>	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	1% Metoceleol in distilled water	WEK
B41793	311	<input type="checkbox"/>	June 2007 - July 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,5	KRG
B41804	312	<input type="checkbox"/>	June 2007 - July 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,5	KRG

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
B47992	313	<input type="checkbox"/>	July 2007 - August 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,5	KRG
C31190	314	<input type="checkbox"/>	Jan. 2009 - July. 2009	Subcutaneous	6	7	150 (±20%)	125 (±20%)	Individually	Kliba 3433	High-density polyethylene	TAT
C57852	315	<input type="checkbox"/>	September 2009	Feeding	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diet	KHE
B31724	316	<input type="checkbox"/>	May 2007 - June 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Acetat Buffer, pH 4,5	KRG
B47968	317	<input type="checkbox"/>	July 2007 - August 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,5	KRG
B05872	318	<input type="checkbox"/>	January 2007 -April 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	KRG
858919	319	<input type="checkbox"/>	March 2005 -January 2006	Gavage	6	7	142.6-153.5	116.0-129.1	Group	Kliba 3433	Dried Corn Oil	PAV
B08741	320	<input type="checkbox"/>	February 2008	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Corn Oil	KOD
B90685	321	<input type="checkbox"/>	April 2008 - July 2008	Gavage	6	5	n.d.	n.d.	Individually	Teklad 2014C	Bi-distilled water	WEK
C05167	322	<input checked="" type="checkbox"/>	April 2008 - September 2008	Gavage	6	5	n.d.	n.d.	Individually	Teklad 2014C	Arachis Oil	WEK
848192	323	<input checked="" type="checkbox"/>	July 2003 - September 2003	Inhalation	6 - 10	2	180 - 200	180 - 200	Group	Kliba 3433	Lactose/Mg Stearate	WEK
B47970	324	<input type="checkbox"/>	July 2007 - November 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,5	KRG
B47981	325	<input type="checkbox"/>	July 2007 - November 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,5	KRG
B50174	326	<input type="checkbox"/>	August 2007 - December 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,0	KRG
C32898	327	<input checked="" type="checkbox"/>	January 2009 -April 2007	Gavage	7	7	170 (±20%)	130 (±20%)	Group	Kliba 3433	0,5% Methylcellulose	IHI
A25435	328	<input checked="" type="checkbox"/>	February 2006 - October 2007	Gavage	6	7	127.1 - 153.3	112.3 - 133.0	Group	Kliba 3433	Sterile water	JAG
857411	329	<input type="checkbox"/>	January 2005 - May 2005	Feeding	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diet	KRG
B12047	330	<input type="checkbox"/>	July 2007 - November 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Corn Oil	KOD
B25064	331	<input checked="" type="checkbox"/>	March 2007 - July 2007	Gavage	6	7	150 (±20%)	120 (±20%)	Group	Kliba 3433	Carboxymethyl cellulose	PAV
A19484	332	<input checked="" type="checkbox"/>	August 2005 - November 2005	Gavage	6	7	142 - 157	114 - 129	Group	Kliba 3433	Bi-distilled water	GPE
B09101	333	<input type="checkbox"/>	January 2007 - June 2007	Gavage	7	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	KOD

Historical Control Data on Histological Findings in 28-days Studies in RccHanTM: Wist, Wistar Hannover Rats

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima- tization (days)	Body Weight: Delivery (g)		Housing	Diet	Vehicle	Pathologist
							M	F				
B33873	334	<input type="checkbox"/>	February 2008 - April 2008	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Polyethylene glycol PEG 300	KOD
B01056	335	<input type="checkbox"/>	November 2006 - April 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Polyethylene glycol PEG 300	KOD
B72101	336	<input type="checkbox"/>	Feb. 2008 - September 2008	Semiocclusive	7	7	170 (±20%)	140 (±20%)	Individually	Kliba 3433	only bandaged	KOD
A46708	337	<input checked="" type="checkbox"/>	May 2006 - September 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Polyethylene glycol PEG 300	KOD
C19578	338	<input checked="" type="checkbox"/>	January 2009 - February 2009	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Bi-distilled water	KOD
B68095	339	<input checked="" type="checkbox"/>	Dec. 2007 - February 2008	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Corn Oil	KRG
C19466	340	<input checked="" type="checkbox"/>	Januar 2009 - February 2009	Gavage	7	8	190 (±20%)	150 (±20%)	Group	Kliba 3433	Bi-distilled water	KOD
	341											
	342											
	343											
	344											
	345											
	346											
	347											

n.d. =no data

Historical Control Data on Histological Findings in 28-days Studies in RccHanTM: Wist, Wistar Hannover Rats

Pathologists:

BDK: Dr. med. vet. K. Bodière, Toxicologic Pathologist
BSC: Dr. med. vet. B. Schlotke, Veterinary Pathologist
CJS: Dr. med. C. Springall, Pathologist
GPZ: Dr. med. vet. G. Pappritz, Veterinary Pathologist
GPE: Dr. G. Pohlmeier-Esch
HHW: Dr. med. vet. H. Westen, Veterinary Pathologist
HJC: Dr. med. vet. H.J. Chevalier, Veterinary Pathologist
IHI: Dr. med. vet. Iwata Hijiri, Veterinary Pathologist
JAG: Dr. med. vet. J. Armstrong, Veterinary Pathologist
JAW: Dr. med. vet. J. Walberg, Veterinary Pathologist
JMA: Dr. med. J. Aluma, Pathologist
KHE: Dr. med. vet. K. Heider, Veterinary Pathologist
KOD: Dr. med. Daniel Konrad, Toxicologic Pathologist
KRG: Dr. med. vet. Dr. G. Krinke, Veterinary Pathologist
LE: Dr. B. Lenz (Sponsor pathologist)
MAM: Dr. med. vet. Martland Malcome, Veterinary Pathologist

MIP: Dr. med. vet. P. Millar, Veterinary Pathologist
NED: Dr. med. vet. D. Nehrbass, Veterinary Pathologist
PAV: Dr. med. vet. V. Pace, Veterinary Pathologist
PIAL: Dr. med. vet. Alessandra Piersigilli, Toxicologic Pathologist
RHA: Dr. R.H. Alison, Toxicologic Pathologist
ROL: Dr. med. L. Romeo, Pathologist
RON: Dr. med. vet. N. Robert, Veterinary Pathologist
RUD: Prof. Dr. med. vet. R. Rudolph, Veterinary Pathologist
SPH: Dr. med. vet. P. Schätti, Veterinary Pathologist
TAT: Dr. med. vet. T. Razinger, Toxicologic Pathologist
THK: Dr. med. vet. T. Hodge, Veterinary Pathologist
VOO: Dr. med. vet. O. Vogel, Veterinary Pathologist
WEK: Dr. rer. nat. K. Weber, Toxicologic Pathologist
WIL: Dr. med. vet. J. T. Wilson, Veterinary Pathologist
WLA: Dr. med. vet. A. Waldvogel, Veterinary Pathologist
WRJ: Dr. med. vet. J. Wright, Veterinary Pathologist

<u>Organ</u>	<u>Page</u>	<u>Organ</u>	<u>Page</u>
Brain	4	Pancreas	29
Cerebrum	4	Liver	30, 31
Brain stem/midbrain	5	Oral cavity	32
Medulla oblangata	5	Tongue	32
Cerebellum	5	Esophagus	33
Pons	6	Stomach	34, 35
Telencephalon	6	Forestomach	36
Spinal cord	6	Glandular stomach	36
Cervical spinal cord	7	Duodenum	37
Lumbar spinal cord	7	Jejunum	37
Thoracic spinal cord	7	Ileum	38
Sciatic nerve	8	Peyer's patches NOS	38
Tibial nerve	8	Peyer's patches - jejunum	39
Optic nerve	8	Peyer's patches - ileum	39
Eyes	9	Caecum	40
Harderian glands	10	Colon	41
Exorbital lacrimal glands	11	Rectum	41
Aorta	1	Salivary glands	42
Heart	12	Parotid salivary glands	42
Nasopharyngeal duct	13	Submandibular salivary glands	43
Nasal cavity	13	Sublingual salivary glands	43
Nasal cavity, level 1	13	Urinary bladder	44
Nasal cavity, level 2	14	Ureter	44
Nasal cavity, level 3	14	Kidneys	45, 46
Nasal cavity, level 4	15	Skin	47
Pharynx	15	Mammary gland	48
Larynx	16	Testes	48
Larynx, level 2	16	Epididymides	49
Larynx, level 3	17	Prostate	49
Larynx, level 4	17	Coagulating glands	49
Larynx, level 5	18	Seminal vesicles	50
Larynx, level 6	18	Ovaries	50
Trachea	19	Oviducts	50
Lungs	20, 21	Uterus	51
Tracheal bifurcation, carina	22	Cervix	51
Main bronchi	22	Vagina	51
Pituitary	23	Bone marrow	52
Adrenals NOS	24	Bone marrow - sternum	52
Adrenal cortex	25, 26	Bone marrow - femur	53
Adrenal medulla	26	Mesenteric lymph nodes	54
Thyroid glands	27	Mandibular lymph nodes	55
Parathyroid glands	28	Mediastinal lymph nodes	56

<u>Organ</u>	<u>Page</u>
Other lymph nodes	57
Thymus	58
Spleen	59
Joint	60
Bone	60
Skeletal muscle	61
Body cavities	61
Adipose tissue	61
Injection sites	62
Injection sites- right	63
Injection sites- left	63
Injection site: tail	64
Injection site: cranial	64
Injection site: caudal	65
Retroorbital tissue	65
Treated skin	66
Untreated skin	66
Skin non-rout untraeted	67
Skin sample 1	67
Skin sample 2	67
Ears	68
Tail	68
Infusion site	68

Brain

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1785					
Ventricular dilation	1	0.06	0.07	1.18	0.00	20.00
Hydrocephalus	3	0.17	0.21	2.04	0.00	20.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Nerve fiber degeneration	1	0.06	0.07	1.18	0.00	20.00
Focal myelomalacia	0	0.00	0.00	0.00	0.00	0.00
Neuronale fixation artefacts	60	3.36	3.66	18.57	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1811					
Ventricular dilation	1	0.06	0.35	5.93	0.00	100.00
Hydrocephalus	5	0.28	0.32	2.43	0.00	20.00
Mononuclear cell foci	1	0.06	0.04	0.59	0.00	10.00
Nerve fiber degeneration	0	0.00	0.00	0.00	0.00	0.00
Focal myelomalacia	0	0.00	0.00	0.00	0.00	0.00
Neuronale fixation artefacts	60	3.31	3.70	18.67	0.00	100.00

Cerebrum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1497					
Ventricular dilation	1	0.07	0.04	0.66	0.00	10.00
Hydrocephalus	1	0.07	0.09	1.32	0.00	20.00
Hemorrhage	8	0.53	0.22	2.72	0.00	40.00
Mononuclear cell foci	1	0.07	0.09	1.32	0.00	20.00
Sateliolosis	1	0.07	0.09	1.32	0.00	20.00
Gliososis	3	0.20	0.26	2.27	0.00	20.00
Pineal hyperplasia	1	0.07	0.04	0.66	0.00	10.00
Neuronale fixation artefacts	5	0.33	0.43	6.59	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1527					
Ventricular dilation	0	0.00	0.00	0.00	0.00	0.00
Hydrocephalus	2	0.13	0.18	2.65	0.00	40.00
Hemorrhage	13	0.85	0.70	6.75	0.00	80.00
Mononuclear cell foci	1	0.07	0.09	1.33	0.00	20.00
Sateliolosis	0	0.00	0.00	0.00	0.00	0.00
Gliososis	0	0.00	0.00	0.00	0.00	0.00
Pineal hyperplasia	0	0.00	0.00	0.00	0.00	0.00
Neuronale fixation artefacts	5	0.33	0.44	6.64	0.00	100.00

Brain stem/midbrain

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1222					
Hemorrhage	1	0.08	0.10	1.45	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1212					
Hemorrhage	3	0.25	0.32	4.35	0.00	60.00

Medulla oblangata

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1188					
Neuronale fixation artefacts	2	0.17	0.23	3.02	0.00	40.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1228					
Neuronale fixation artefacts	1	0.08	0.11	1.52	0.00	20.00

Cerebellum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1552					
Hydrocephalus	1	0.06	0.08	1.29	0.00	20.00
Hemorrhage	5	0.32	0.41	4.26	0.00	60.00
Mononuclear cell foci	1	0.06	0.08	1.29	0.00	20.00
Satellitosis	1	0.06	0.08	1.29	0.00	20.00
Vacuolation	0	0.00	0.00	0.00	0.00	0.00
Neuronale fixation artefacts	3	0.19	0.25	3.86	0.00	60.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1592					
Hydrocephalus	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	4	0.25	0.29	2.96	0.00	40.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Satellitosis	1	0.06	0.08	1.29	0.00	20.00
Vacuolation	1	0.06	0.08	1.29	0.00	20.00
Neuronale fixation artefacts	10	0.63	0.42	6.47	0.00	100.00

Pons

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1274					
Neurophil vacuolation	2	0.16	0.21	2.86	0.00	40.00
Neuronale fixation artefacts	1	0.08	0.10	1.43	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1323					
Neurophil vacuolation	0	0.00	0.00	0.00	0.00	0.00
Neuronale fixation artefacts	0	0.00	0.00	0.00	0.00	0.00

Telencephalon

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1003					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	983					

Spinal cord

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1568					
Hemorrhage	1	0.06	0.08	1.26	0.00	20.00
Dilated lumen, central channel	1	0.06	0.04	0.63	0.00	10.00
Fixation artefacts	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1620					
Hemorrhage	1	0.06	0.00	0.00	0.00	0.00
Dilated lumen, central channel	0	0.00	0.00	0.00	0.00	0.00
Fixation artefacts	5	0.31	0.40	6.31	0.00	100.00

Cervical spinal cord

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	649					
Hemorrhage	2	0.31	0.46	3.01	0.00	20.00
Satellitosis	1	0.15	0.23	2.14	0.00	20.00
Single fiber degeneration	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	619					
Hemorrhage	1	0.16	0.12	1.09	0.00	10.00
Satellitosis	0	0.00	0.00	0.00	0.00	0.00
Single fiber degeneration	1	0.16	0.08	0.73	0.00	6.67

Lumbar spinal cord

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	639					
Hemorrhage	1	0.16	0.23	2.16	0.00	20.00
Satellitosis	1	0.16	0.23	2.16	0.00	20.00
Single fiber degeneration	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	628					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Satellitosis	2	0.32	0.47	3.05	0.00	20.00
Single fiber degeneration	1	0.16	0.04	0.37	0.00	3.45

Thoracic spinal cord

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	619					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Neuronal degeneration	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	609					
Hemorrhage	6	0.99	0.47	3.05	0.00	20.00
Neuronal degeneration	1	0.16	0.12	1.08	0.00	10.00

Sciatic nerve

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1899					
Ectopic neurons	4	0.21	0.24	2.09	0.00	20.00
Hemorrhage	1	0.05	0.07	1.16	0.00	20.00
Mononuclear cell foci	1	0.05	0.07	1.16	0.00	20.00
Nerve fiber degeneration	100	5.27	5.20	11.26	0.00	80.00
Neurophagia	1	0.05	0.07	1.16	0.00	20.00
Mast cell	4	0.21	0.27	4.65	0.00	80.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1933					
Ectopic neurons	2	0.10	0.14	1.65	0.00	20.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Nerve fiber degeneration	172	8.90	9.64	16.02	0.00	80.00
Neurophagia	1	0.05	0.07	1.17	0.00	20.00
Mast cell	5	0.26	0.34	5.83	0.00	100.00

Tibial nerve

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	40					
Single fiber degeneration	3	7.50	7.14	14.96	0.00	40.00
Bacteria	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	40					
Single fiber degeneration	1	2.50	2.86	7.56	0.00	20.00
Bacteria	1	2.50	1.43	3.78	0.00	10.00

Optic nerve

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	798					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	863					

Eyes

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	880					
Persistent hyaloid artery	1	0.11	0.09	0.96	0.00	10.00
Retinal rosettes	15	1.70	1.48	5.26	0.00	30.00
Traumatic ablation, cornea	1	0.11	0.09	0.96	0.00	10.00
Hemorrhage, retro-orbital	175	19.89	16.23	26.74	0.00	80.00
Hemosiderin	2	0.23	0.19	1.35	0.00	10.00
Corneal foreign body	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	1	0.11	0.09	0.96	0.00	10.00
Conjunctivitis	3	0.34	0.28	2.14	0.00	20.00
Retinal degeneration	7	0.80	0.54	4.03	0.00	40.00
Lenticular degeneration	0	0.00	0.00	0.00	0.00	0.00
Corneal ulceration	0	0.00	0.00	0.00	0.00	0.00
Keratitis	0	0.00	0.00	0.00	0.00	0.00
Fibrosis	3	0.34	0.28	1.65	0.00	10.00
Inflammation, periorbital	96	10.91	8.36	16.96	0.00	90.00
Phthisis bulbi	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	940					
Persistent hyaloid artery	3	0.32	0.37	2.34	0.00	20.00
Retinal rosettes	12	1.28	1.30	5.31	0.00	40.00
Traumatic ablation, cornea	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage, retro-orbital	215	22.87	20.21	31.58	0.00	100.00
Hemosiderin	0	0.00	0.00	0.00	0.00	0.00
Corneal foreign body	1	0.11	0.09	0.96	0.00	10.00
Mononuclear cell foci	6	0.64	0.56	3.01	0.00	20.00
Conjunctivitis	3	0.32	0.28	2.89	0.00	30.00
Retinal degeneration	4	0.43	0.37	2.34	0.00	20.00
Lenticular degeneration	3	0.32	0.28	1.65	0.00	10.00
Corneal ulceration	1	0.11	0.09	0.96	0.00	10.00
Keratitis	1	0.11	0.09	0.96	0.00	10.00
Fibrosis	2	0.21	0.19	1.35	0.00	10.00
Inflammation, periorbital	90	9.57	7.91	15.56	0.00	80.00
Phthisis bulbi	1	0.11	0.09	0.96	0.00	10.00

Harderian glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	704					
Glandular dilation	3	0.43	0.33	2.33	0.00	20.00
Porphyrin deposition	162	23.01	16.04	29.21	0.00	100.00
Hemosiderin	2	0.28	0.22	1.47	0.00	10.00
Hemorrhage	85	12.07	10.01	22.30	0.00	100.00
Mononuclear cell foci	3	0.43	0.11	1.05	0.00	10.00
Inflammatory cell foci	5	0.71	0.22	1.47	0.00	10.00
Inflammation	35	4.97	6.26	19.32	0.00	100.00
Atrophy	1	0.14	0.11	1.05	0.00	10.00
Hyperplasia	1	0.14	1.10	10.48	0.00	100.00
Porphyrin granulomas	8	1.14	1.21	8.14	0.00	60.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	766					
Glandular dilation	1	0.13	0.00	0.00	0.00	0.00
Porphyrin deposition	153	19.97	15.20	29.10	0.00	100.00
Hemosiderin	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	82	10.70	8.97	18.37	0.00	70.00
Mononuclear cell foci	17	2.22	1.74	14.72	0.00	140.00
Inflammatory cell foci	5	0.65	0.55	4.31	0.00	40.00
Inflammation	52	6.79	7.63	19.82	0.00	100.00
Atrophy	0	0.00	0.00	0.00	0.00	0.00
Hyperplasia	1	0.13	0.37	3.49	0.00	33.33
Porphyrin granulomas	9	1.17	1.21	7.58	0.00	60.00

Exorbital lacrimal glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	589					
Harderian alteration	21	3.57	2.28	5.76	0.00	30.00
Secretory hyperactivity	0	0.00	0.00	0.00	0.00	0.00
Cytomegaly	1	0.17	0.13	1.14	0.00	10.00
Hemorrhage	1	0.17	1.30	11.40	0.00	100.00
Acinar hypertrophy	1	0.17	0.05	0.47	0.00	4.17
Mononuclear cell foci	4	0.68	0.45	2.02	0.00	10.00
Inflammatory foci	1	0.17	0.13	1.14	0.00	10.00
Necrosis	1	0.17	0.13	1.14	0.00	10.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00
Harderian glandular change	5	0.85	0.65	4.08	0.00	30.00
Atrophy: focal	1	0.17	0.05	0.47	0.00	4.17

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	589					
Harderian alteration	9	1.53	0.99	3.37	0.00	20.00
Secretory hyperactivity	2	0.34	0.26	2.29	0.00	20.00
Cytomegaly	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Acinar hypertrophy	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	3	0.51	0.26	1.39	0.00	10.00
Inflammatory foci	0	0.00	0.00	0.00	0.00	0.00
Necrosis	0	0.00	0.00	0.00	0.00	0.00
Inflammation	2	0.34	0.26	1.61	0.00	10.00
Harderian glandular change	6	1.02	0.79	3.92	0.00	30.00
Atrophy: focal	0	0.00	0.00	0.00	0.00	0.00

Aorta

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	719					
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	789					
Mononuclear cell foci	1	0.13	0.11	1.04	0.00	10.00

Heart

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2046					
Congestion	0	0.00	0.00	0.00	0.00	0.00
Lymphangiectasis	1	0.05	0.06	1.11	0.00	20.00
Hemopoietic cell foci	1	0.05	0.03	0.56	0.00	10.00
Mononuclear cell foci	159	7.77	7.50	14.01	0.00	60.00
Inflammatory cell foci	71	3.47	3.31	9.51	0.00	60.00
Thrombosis	2	0.10	0.06	1.11	0.00	20.00
Cartilaginous metaplasia	0	0.00	0.00	0.00	0.00	0.00
Valvular mucoid degeneration	0	0.00	0.00	0.00	0.00	0.00
Myofibrosis/necrosis	26	1.27	1.55	6.42	0.00	40.00
Myocardial necrosis	52	2.54	2.09	7.04	0.00	60.00
Myocardial fibrosis	8	0.39	0.31	2.07	0.00	20.00
Inflammation	10	0.49	0.47	4.04	0.00	50.00
Progressive cardiomyopathy	6	0.29	0.22	1.84	0.00	20.00
Inflammation / Fibrosis	2	0.10	0.09	1.24	0.00	20.00
Valvular endocardiosis	1	0.05	0.06	1.11	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2085					
Congestion	2	0.10	0.13	2.24	0.00	40.00
Lymphangiectasis	1	0.05	0.06	1.12	0.00	20.00
Hemopoietic cell foci	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	80	3.84	3.61	10.10	0.00	60.00
Inflammatory cell foci	54	2.59	2.66	9.00	0.00	80.00
Thrombosis	0	0.00	0.00	0.00	0.00	0.00
Cartilaginous metaplasia	1	0.05	0.03	0.56	0.00	10.00
Valvular mucoid degeneration	1	0.05	0.06	1.12	0.00	20.00
Myofibrosis/necrosis	9	0.43	0.53	3.55	0.00	40.00
Myocardial necrosis	17	0.82	0.59	3.06	0.00	20.00
Myocardial fibrosis	7	0.34	0.28	2.42	0.00	30.00
Inflammation	2	0.10	0.13	1.58	0.00	20.00
Progressive cardiomyopathy	3	0.14	0.09	1.25	0.00	20.00
Inflammation / Fibrosis	0	0.00	0.00	0.00	0.00	0.00
Valvular endocardiosis	1	0.05	0.06	1.12	0.00	20.00

Nasopharyngeal duct

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	196					
Mucous plug	0	0.00	0.00	0.00	0.00	0.00
Goblet cell proliferation	3	1.53	1.88	5.44	0.00	20.00
Periductal inflammation	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	196					
Mucous plug	1	0.51	0.63	2.50	0.00	10.00
Goblet cell proliferation	4	2.04	2.50	10.00	0.00	40.00
Periductal inflammation	1	0.51	0.52	2.08	0.00	8.33

Nasal cavity

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	522					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	582					

Nasal cavity, level 1

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	284					
Goblet cell proliferation	28	9.86	7.25	18.22	0.00	90.00
Cellular detritus	1	0.35	0.17	0.91	0.00	5.00
Vaneronasal organ, necrosis	8	2.82	2.67	14.61	0.00	80.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	284					
Goblet cell proliferation	20	7.04	5.94	15.66	0.00	80.00
Cellular detritus	1	0.35	0.17	0.91	0.00	5.00
Vaneronasal organ, necrosis	0	0.00	0.00	0.00	0.00	0.00

Nasal cavity, level 2

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	296					
Foreign body	0	0.00	0.00	0.00	0.00	0.00
Cellular detritus	4	1.35	0.97	3.96	0.00	20.00
Goblet cell proliferation	6	2.03	1.88	5.35	0.00	20.00
Vaneronasal organ, necrosis	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	296					
Foreign body	1	0.34	0.16	0.90	0.00	5.00
Cellular detritus	3	1.01	0.81	2.61	0.00	10.00
Goblet cell proliferation	5	1.69	1.45	5.66	0.00	30.00
Vaneronasal organ, necrosis	4	1.35	1.29	7.18	0.00	40.00

Nasal cavity, level 3

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	244					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Cellular detritus	4	1.64	1.15	4.31	0.00	20.00
Goblet cell proliferation	5	2.05	1.92	6.94	0.00	30.00
Inflammatory cell foci	0	0.00	0.00	0.00	0.00	0.00
Vaneronasal organ, necrosis	1	0.41	0.38	1.96	0.00	10.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	314					
Hemorrhage	1	0.32	0.37	1.92	0.00	10.00
Cellular detritus	2	0.64	0.56	2.12	0.00	10.00
Goblet cell proliferation	2	0.64	0.74	3.85	0.00	20.00
Inflammatory cell foci	1	0.32	0.74	3.85	0.00	20.00
Vaneronasal organ, necrosis	1	0.32	0.37	1.92	0.00	10.00

Nasal cavity, level 4

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	204					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Epithelial degeneration	1	0.49	0.42	2.04	0.00	10.00
Eosinophilic inclusions	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	204					
Hemorrhage	1	0.49	0.42	2.04	0.00	10.00
Epithelial degeneration	0	0.00	0.00	0.00	0.00	0.00
Eosinophilic inclusions	1	0.49	0.17	0.85	0.00	4.17

Pharynx

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	191					
Scab	1	0.52	0.53	2.29	0.00	10.00
Mononuclear cell foci	1	0.52	1.05	4.59	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	191					
Scab	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00

Larynx

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	578					
Glandular dilation	7	1.21	0.92	6.15	0.00	50.00
Foreign bodies	0	0.00	0.00	0.00	0.00	0.00
Inspissated secretion in ventral pouch	1	0.17	0.13	1.15	0.00	10.00
Dessicated secretion	2	0.35	0.26	2.29	0.00	20.00
Mononuclear cell foci	14	2.42	1.84	11.97	0.00	100.00
Erosion	0	0.00	0.00	0.00	0.00	0.00
Inflammation	1	0.17	0.13	1.15	0.00	10.00
Inflammatory cell foci	14	2.42	1.58	7.84	0.00	60.00
Inflamm. Cell infiltrartion	4	0.69	0.53	4.59	0.00	40.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	578					
Glandular dilation	11	1.90	1.45	10.55	0.00	90.00
Foreign bodies	1	0.17	0.13	1.15	0.00	10.00
Inspissated secretion in ventral pouch	0	0.00	0.00	0.00	0.00	0.00
Dessicated secretion	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	14	2.42	1.84	11.97	0.00	100.00
Erosion	1	0.17	0.13	1.15	0.00	10.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell foci	11	1.90	1.18	7.30	0.00	60.00
Inflamm. Cell infiltrartion	5	0.87	0.66	5.74	0.00	50.00

Larynx, level 2

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	115					
Disseccated secretion	1	0.87	0.31	1.16	0.00	4.35
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Inflammation	6	5.22	3.88	9.23	0.00	30.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	115					
Disseccated secretion	1	0.87	0.31	1.16	0.00	4.35
Mononuclear cell foci	1	0.87	0.60	2.23	0.00	8.33
Inflammation	4	3.48	2.74	5.98	0.00	20.00

Larynx, level 3

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	135					
Dissected secretion	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	2	1.48	0.89	2.43	0.00	8.33
Inflammation	1	0.74	0.29	1.12	0.00	4.35

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	134					
Dissected secretion	2	1.49	0.61	2.35	0.00	9.09
Mononuclear cell foci	5	3.73	2.11	5.58	0.00	16.67
Inflammation	1	0.75	0.56	2.15	0.00	8.33

Larynx, level 4

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	19					
Hemorrhage in lumen	1	5.26	5.26	0.00	5.26	5.26
Dissected secretion	1	5.26	5.26	0.00	5.26	5.26
Mononuclear cell foci	7	36.84	36.84	0.00	36.84	36.84
Granuloma	1	5.26	5.26	0.00	5.26	5.26
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	19					
Hemorrhage in lumen	0	0.00	0.00	0.00	0.00	0.00
Dissected secretion	1	5.26	5.26	0.00	5.26	5.26
Mononuclear cell foci	1	5.26	5.26	0.00	5.26	5.26
Granuloma	0	0.00	0.00	0.00	0.00	0.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Larynx, level 5

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	17					
Hemorrhage in lumen	1	5.88	5.88	0.00	5.88	5.88
Mononuclear cell foci	7	41.18	41.18	0.00	41.18	41.18
Granuloma	1	5.88	5.88	0.00	5.88	5.88
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	17					
Hemorrhage in lumen	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	4	23.53	23.53	0.00	23.53	23.53
Granuloma	0	0.00	0.00	0.00	0.00	0.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Larynx, level 6

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	126					
Squamoid epithelium	18	14.29	7.27	17.72	0.00	59.09
Hemorrhage in lumen	1	0.79	0.30	1.17	0.00	4.55
Mononuclear cell foci	2	1.59	0.70	2.72	0.00	10.53

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	120					
Squamoid epithelium	12	10.00	5.08	13.88	0.00	47.62
Hemorrhage in lumen	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00

Trachea

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1888					
Distended glands	242	12.82	12.11	19.10	0.00	80.00
Eosinophilic inclusions	39	2.07	2.65	15.23	0.00	100.00
Mononuclear cell foci	183	9.69	9.26	19.20	0.00	90.00
Inflammatory cell foci	127	6.73	7.41	22.20	0.00	100.00
Inflammation	28	1.48	1.50	11.26	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1918					
Distended glands	249	12.98	13.45	20.74	0.00	100.00
Eosinophilic inclusions	35	1.82	2.40	13.61	0.00	100.00
Mononuclear cell foci	169	8.81	8.96	20.15	0.00	100.00
Inflammatory cell foci	119	6.20	7.21	21.48	0.00	100.00
Inflammation	19	0.99	0.96	7.85	0.00	80.00

Lungs

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1979					
Foreign bodies	2	0.10	0.13	2.27	0.00	40.00
Collapse	3	0.15	0.19	1.96	0.00	20.00
Osseous metaplasia	73	3.69	3.99	8.18	0.00	40.00
Alveolar mineralization	3	0.15	0.10	1.70	0.00	30.00
Vascular mineralization	384	19.40	18.53	26.61	0.00	120.00
Mineralization	20	1.01	1.03	7.42	0.00	80.00
Congestion	11	0.56	0.40	2.39	0.00	20.00
Hemorrhage	67	3.39	3.63	9.89	0.00	80.00
Alveolar edema	1	0.05	0.06	1.13	0.00	20.00
Atelectasis	5	0.25	0.32	2.99	0.00	40.00
Emphysema, acute	22	1.11	0.89	6.15	0.00	80.00
Alveolar crystals	2	0.10	0.13	1.60	0.00	20.00
Bronchial exudate	1	0.05	0.03	0.57	0.00	10.00
Alveolar histiocytosis	495	25.01	25.55	29.17	0.00	140.00
Phagocytic cells	1	0.05	0.06	1.13	0.00	20.00
Perivascular cuffing	42	2.12	2.48	9.60	0.00	60.00
Cytoplasmic inclusions	2	0.10	0.13	2.27	0.00	40.00
Inflammatory cell foci	66	3.34	3.00	10.58	0.00	80.00
Alveolitis	99	5.00	5.68	15.44	0.00	100.00
Granulomas	17	0.86	0.75	5.61	0.00	80.00
Abscess	1	0.05	0.02	0.44	0.00	7.69
Occluded arterioles	1	0.05	0.03	0.57	0.00	10.00
Pleural fibrosis	2	0.10	0.13	1.60	0.00	20.00
Lymphoid hyperplasia	43	2.17	2.73	10.68	0.00	80.00
Focal bronch hyperplasia	1	0.05	0.03	0.57	0.00	10.00
Alveolar hyperplasia	2	0.10	0.06	1.13	0.00	20.00
Mononuclear cell foci	132	6.67	7.18	15.98	0.00	100.00
Perivascular inflammation	36	1.82	2.04	9.39	0.00	80.00
Inflammation	10	0.51	0.46	2.93	0.00	23.08
Interstitial inflammation	6	0.30	0.34	3.00	0.00	40.00
Thrombosis	3	0.15	0.11	1.43	0.00	20.00
Interstitial fibrosis	1	0.05	0.06	1.13	0.00	20.00
Bronchiolitis	0	0.00	0.00	0.00	0.00	0.00
Vasculitis / Perivasculitis	7	0.35	0.26	2.77	0.00	40.00
Hyaline inclusions	0	0.00	0.00	0.00	0.00	0.00
Alveolar granuloma	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1999					
Foreign bodies	0	0.00	0.00	0.00	0.00	0.00
Collapse	2	0.10	0.13	1.61	0.00	20.00
Osseous metaplasia	41	2.05	2.05	5.88	0.00	30.00
Alveolar mineralization	7	0.35	0.29	3.64	0.00	50.00
Vascular mineralization	268	13.41	13.00	21.45	0.00	120.00
Mineralization	19	0.95	1.04	6.82	0.00	60.00
Congestion	3	0.15	0.10	1.27	0.00	20.00
Hemorrhage	35	1.75	1.88	8.29	0.00	100.00
Alveolar edema	1	0.05	0.06	1.14	0.00	20.00
Atelectasis	5	0.25	0.34	2.67	0.00	25.00
Emphysema, acute	26	1.30	1.24	5.36	0.00	60.00
Alveolar crystals	2	0.10	0.06	1.14	0.00	20.00
Bronchial exudate	2	0.10	0.13	1.61	0.00	20.00
Alveolar histiocytosis	465	23.26	26.31	57.58	0.00	900.00
Phagocytic cells	0	0.00	0.00	0.00	0.00	0.00
Perivascular cuffing	44	2.20	2.50	10.55	0.00	80.00
Cytoplasmic inclusions	1	0.05	0.06	1.14	0.00	20.00
Inflammatory cell foci	60	3.00	3.46	15.58	0.00	200.00
Alveolitis	74	3.70	4.21	12.55	0.00	100.00
Granulomas	10	0.50	0.45	4.09	0.00	40.00
Abscess	0	0.00	0.00	0.00	0.00	0.00
Occluded arterioles	0	0.00	0.00	0.00	0.00	0.00
Pleural fibrosis	2	0.10	0.10	1.27	0.00	20.00
Lymphoid hyperplasia	27	1.35	1.75	8.74	0.00	80.00
Focal bronch hyperplasia	0	0.00	0.00	0.00	0.00	0.00
Alveolar hyperplasia	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	113	5.65	6.40	15.69	0.00	90.00
Perivascular inflammation	29	1.45	1.69	9.21	0.00	100.00
Inflammation	6	0.30	0.32	2.40	0.00	20.00
Interstitial inflammation	5	0.25	0.28	3.61	0.00	60.00
Thrombosis	2	0.10	0.13	1.61	0.00	20.00
Interstitial fibrosis	1	0.05	0.06	1.14	0.00	20.00
Bronchiolitis	1	0.05	0.06	1.14	0.00	20.00
Vasculitis / Perivasculitis	4	0.20	0.16	1.70	0.00	20.00
Hyaline inclusions	1	0.05	0.06	1.14	0.00	20.00
Alveolar granuloma	1	0.05	0.06	1.14	0.00	20.00

Tracheal bifurcation, carina

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	24					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	24					

Main bronchi

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	41					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	41					

Pituitary

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	956					
Stomatodeal remnants	0	0.00	0.00	0.00	0.00	0.00
Cyst	61	6.38	5.11	8.73	0.00	40.00
Cystic Rathke`s cleft	9	0.94	0.80	5.08	0.00	50.00
Vacuolation, pars anterior	8	0.84	0.92	6.64	0.00	60.00
Angiectasis	1	0.10	0.08	0.92	0.00	10.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Gliosis	1	0.10	0.08	0.92	0.00	10.00
Atrophy	1	0.10	0.08	0.92	0.00	10.00
Hyperplasia, diffuse	0	0.00	0.00	0.00	0.00	0.00
TSH-Cell hypertrophy	6	0.63	0.50	5.50	0.00	60.00
Macrophages, Rathke`s cleft	0	0.00	0.00	0.00	0.00	0.00
Hypertrophy, intermedialis	1	0.10	0.08	0.92	0.00	10.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	987					
Stomatodeal remnants	2	0.20	0.17	1.31	0.00	10.00
Cyst	49	4.96	4.17	7.39	0.00	30.00
Cystic Rathke`s cleft	20	2.03	1.57	6.54	0.00	40.00
Vacuolation, pars anterior	1	0.10	0.09	0.93	0.00	10.00
Angiectasis	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	1	0.10	0.09	0.93	0.00	10.00
Gliosis	0	0.00	0.00	0.00	0.00	0.00
Atrophy	0	0.00	0.00	0.00	0.00	0.00
Hyperplasia, diffuse	2	0.20	0.14	1.55	0.00	16.67
TSH-Cell hypertrophy	1	0.10	0.09	0.93	0.00	10.00
Macrophages, Rathke`s cleft	0	0.00	0.00	0.00	0.00	0.00
Hypertrophy, intermedialis	0	0.00	0.00	0.00	0.00	0.00

Adrenals NOS

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1650					
Extra-adrenal tissue	4	0.24	0.22	1.93	0.00	20.00
Dilated vessels	0	0.00	0.00	0.00	0.00	0.00
Vacuolation	91	5.52	5.73	18.63	0.00	100.00
Mononuclear cell foci	1	0.06	0.04	0.61	0.00	10.00
Hypertrophy, diffuse	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1699					
Extra-adrenal tissue	4	0.24	0.30	2.44	0.00	20.00
Dilated vessels	3	0.18	0.23	3.68	0.00	60.00
Vacuolation	7	0.41	0.45	3.33	0.00	40.00
Mononuclear cell foci	2	0.12	0.11	1.37	0.00	20.00
Hypertrophy, diffuse	2	0.12	0.11	1.37	0.00	20.00

Adrenal cortex

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1978					
Additional adrenal	0	0.00	0.00	0.00	0.00	0.00
Cyst(s)	0	0.00	0.00	0.00	0.00	0.00
Extra-adrenal tissue	26	1.31	1.30	4.98	0.00	40.00
Osseous metaplasia	1	0.05	0.03	0.56	0.00	10.00
Congestion	3	0.15	0.10	1.26	0.00	20.00
Mineralization	4	0.20	0.25	2.24	0.00	20.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Ceroid deposits	1	0.05	0.06	1.13	0.00	20.00
Pigment, zona reticularis	1	0.05	0.03	0.56	0.00	10.00
Vacuolation	644	32.56	31.79	34.80	0.00	140.00
Angiectasis	2	0.10	0.13	1.59	0.00	20.00
Hemorrhagic cyst	0	0.00	0.00	0.00	0.00	0.00
Eosinophilic inclusion	0	0.00	0.00	0.00	0.00	0.00
Increased apoptosis	0	0.00	0.00	0.00	0.00	0.00
Necrosis	0	0.00	0.00	0.00	0.00	0.00
Hemopoietic foci	2	0.10	0.10	1.26	0.00	20.00
Mononuclear cell foci	14	0.71	0.57	2.93	0.00	20.00
Inflammatory cell foci	1	0.05	0.06	1.13	0.00	20.00
Inflammation	1	0.05	0.03	0.56	0.00	10.00
Fibrosis	1	0.05	0.06	1.13	0.00	20.00
Capsular fibrosis	1	0.05	0.06	1.13	0.00	20.00
Hypertrophy	4	0.20	0.25	3.56	0.00	60.00
Hypertrophy, zona glomerulosa	5	0.25	0.22	2.32	0.00	30.00
Hypertrophy, zona fasciculata	11	0.56	0.48	5.30	0.00	70.00
Hyperplasia, focal	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2011					
Additional adrenal	1	0.05	0.01	0.24	0.00	4.17
Cyst(s)	2	0.10	0.10	1.26	0.00	20.00
Extra-adrenal tissue	29	1.44	1.68	7.50	0.00	100.00
Osseous metaplasia	1	0.05	0.06	1.13	0.00	20.00
Congestion	1	0.05	0.03	0.57	0.00	10.00
Mineralization	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	1	0.05	0.06	1.13	0.00	20.00
Ceroid deposits	0	0.00	0.00	0.00	0.00	0.00
Pigment, zona reticularis	0	0.00	0.00	0.00	0.00	0.00
Vacuolation	87	4.33	4.84	15.72	0.00	100.00
Angiectasis	2	0.10	0.04	0.57	0.00	10.00
Hemorrhagic cyst	1	0.05	0.00	0.07	0.00	1.25
Eosinophilic inclusion	1	0.05	0.06	1.13	0.00	20.00
Increased apoptosis	1	0.05	0.06	1.13	0.00	20.00
Necrosis	1	0.05	0.03	0.57	0.00	10.00
Hemopoietic foci	3	0.15	0.09	0.92	0.00	10.00
Mononuclear cell foci	32	1.59	1.23	4.97	0.00	40.00
Inflammatory cell foci	1	0.05	0.06	1.13	0.00	20.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00
Fibrosis	0	0.00	0.00	0.00	0.00	0.00
Capsular fibrosis	1	0.05	0.06	1.13	0.00	20.00
Hypertrophy	4	0.20	0.22	2.58	0.00	40.00
Hypertrophy, zona glomerulosa	2	0.10	0.06	1.13	0.00	20.00
Hypertrophy, zona fasciculata	9	0.45	0.51	4.43	0.00	60.00
Hyperplasia, focal	1	0.05	0.00	0.07	0.00	1.25

Adrenal medulla

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1872					
Vacuolation	1	0.05	0.07	1.16	0.00	20.00
Mononuclear cell foci	1	0.05	0.03	0.58	0.00	10.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1914					
Vacuolation	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00

Thyroid glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2009					
Anomaly	2	0.10	0.07	0.81	0.00	10.00
Dysplasia	17	0.85	0.64	3.93	0.00	40.00
Ductal remnant	49	2.44	2.84	9.98	0.00	100.00
Thymic remnant	105	5.23	5.14	10.22	0.00	60.00
Ectopic lymph node	1	0.05	0.07	1.14	0.00	20.00
Colloid alteration	4	0.20	0.26	2.79	0.00	40.00
Follicular cyst	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	18	0.90	1.00	4.76	0.00	40.00
Activation	9	0.45	0.59	4.96	0.00	60.00
Synthesis phase	3	0.15	0.20	3.43	0.00	60.00
Storage phase	2	0.10	0.13	2.29	0.00	40.00
Reabsorbtion phase	0	0.00	0.00	0.00	0.00	0.00
Inflammation	2	0.10	0.10	1.28	0.00	20.00
Follicular cell hypertrophy	110	5.48	6.63	20.46	0.00	100.00
Follicular hyperplasia	1	0.05	0.04	0.64	0.00	11.11
Vacuolation, cytoplasmic	0	0.00	0.00	0.00	0.00	0.00
Hyperplasia C-Cell	1	0.05	0.07	1.14	0.00	20.00
Nodule	0	0.00	0.00	0.00	0.00	0.00
Fibrosis	1	0.05	0.07	1.14	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1985					
Anomaly	2	0.10	0.07	0.81	0.00	10.00
Dysplasia	24	1.21	1.11	5.93	0.00	40.00
Ductal remnant	77	3.88	4.02	10.34	0.00	100.00
Thymic remnant	81	4.08	4.17	9.61	0.00	80.00
Ectopic lymph node	0	0.00	0.00	0.00	0.00	0.00
Colloid alteration	3	0.15	0.20	1.99	0.00	20.00
Follicular cyst	3	0.15	0.20	2.57	0.00	40.00
Mononuclear cell foci	8	0.40	0.35	2.30	0.00	20.00
Activation	1	0.05	0.07	1.15	0.00	20.00
Synthesis phase	1	0.05	0.07	1.15	0.00	20.00
Storage phase	3	0.15	0.20	3.46	0.00	60.00
Reabsorbtion phase	1	0.05	0.07	1.15	0.00	20.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00
Follicular cell hypertrophy	54	2.72	2.94	10.59	0.00	80.00
Follicular hyperplasia	1	0.05	0.07	1.15	0.00	20.00
Vacuolation, cytoplasmic	1	0.05	0.03	0.58	0.00	10.00
Hyperplasia C-Cell	2	0.10	0.13	1.63	0.00	20.00
Nodule	1	0.05	0.03	0.58	0.00	10.00
Fibrosis	0	0.00	0.00	0.00	0.00	0.00

Parathyroid glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1824					
Fibrosis	0	0.00	0.00	0.00	0.00	0.00
Degeneration	0	0.00	0.00	0.00	0.00	0.00
Oxyphil cells	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	2	0.11	0.14	1.66	0.00	20.00
Thymic remnants	1	0.05	0.04	0.73	0.00	12.50
Ectopic lymph node	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1854					
Fibrosis	6	0.32	0.37	2.87	0.00	28.57
Degeneration	1	0.05	0.04	0.74	0.00	12.50
Oxyphil cells	1	0.05	0.04	0.74	0.00	12.50
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Thymic remnants	0	0.00	0.00	0.00	0.00	0.00
Ectopic lymph node	1	0.05	0.02	0.37	0.00	6.25

Pancreas

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	890					
Congestion	3	0.34	0.29	1.77	0.00	12.50
Zymogen decreased	1	0.11	0.18	1.89	0.00	20.00
Ductular dilation	1	0.11	0.09	0.94	0.00	10.00
Acinar cell vacuolation	9	1.01	1.07	7.02	0.00	60.00
Mononuclear cell foci	28	3.15	2.68	11.39	0.00	90.00
Inflammatory cell foci	2	0.22	0.36	3.78	0.00	40.00
Apoptosis	1	0.11	0.09	0.94	0.00	10.00
Exocrine atrophy	26	2.92	2.50	6.22	0.00	40.00
Islet cell degeneration	1	0.11	0.09	0.94	0.00	10.00
Fatty atrophy	4	0.45	0.36	3.78	0.00	40.00
Multinuclear giant cells	1	0.11	0.09	0.94	0.00	10.00
Thrombosis	1	0.11	0.09	0.94	0.00	10.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00
Basophilic focus	2	0.22	0.09	0.94	0.00	10.00
Exocrine hypertrophy	1	0.11	0.04	0.47	0.00	5.00
Islet cell hyperplasia	6	0.67	0.54	4.81	0.00	50.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	951					
Congestion	4	0.42	1.23	9.61	0.00	100.00
Zymogen decreased	2	0.21	0.35	3.75	0.00	40.00
Ductular dilation	0	0.00	0.00	0.00	0.00	0.00
Acinar cell vacuolation	7	0.74	0.96	5.32	0.00	40.00
Mononuclear cell foci	20	2.10	1.93	9.30	0.00	80.00
Inflammatory cell foci	3	0.32	0.44	3.85	0.00	40.00
Apoptosis	1	0.11	0.09	0.94	0.00	10.00
Exocrine atrophy	34	3.58	2.92	6.87	0.00	40.00
Islet cell degeneration	0	0.00	0.00	0.00	0.00	0.00
Fatty atrophy	1	0.11	0.09	0.94	0.00	10.00
Multinuclear giant cells	0	0.00	0.00	0.00	0.00	0.00
Thrombosis	0	0.00	0.00	0.00	0.00	0.00
Inflammation	2	0.21	0.18	1.32	0.00	10.00
Basophilic focus	0	0.00	0.00	0.00	0.00	0.00
Exocrine hypertrophy	0	0.00	0.00	0.00	0.00	0.00
Islet cell hyperplasia	2	0.21	0.26	2.09	0.00	20.00

Liver

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2137					
Malformation	1	0.05	0.06	1.09	0.00	20.00
Hepatodiaphragmatic herniation	0	0.00	0.00	0.00	0.00	0.00
Congestion	4	0.19	0.15	1.63	0.00	20.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Glycogen deposition	150	7.02	6.64	21.99	0.00	100.00
Fatty change	418	19.56	21.17	31.58	0.00	100.00
Vacuolation	36	1.68	1.94	8.62	0.00	60.00
Sinusoidal dilation	1	0.05	0.02	0.42	0.00	7.69
Increased basophila	11	0.51	0.33	5.49	0.00	100.00
Hemopoietic cell foci	8	0.37	0.25	2.60	0.00	40.00
Erythropoiesis	178	8.33	8.71	16.45	0.00	120.00
Megakaryocytes	2	0.09	0.12	1.54	0.00	20.00
Pigment deposition	7	0.33	0.39	2.71	0.00	20.00
Hemosiderin	4	0.19	0.21	2.50	0.00	40.00
Necrosis	16	0.75	0.77	4.50	0.00	60.00
Hyaline inclusions	3	0.14	0.18	2.44	0.00	40.00
Cholestasis	2	0.09	0.12	2.19	0.00	40.00
Inflammatory cell foci	1415	66.21	66.77	34.01	0.00	140.00
Multinucleated giant cells	3	0.14	0.18	2.44	0.00	40.00
Single cell necrosis	82	3.84	4.49	16.16	0.00	100.00
Apoptosis	1	0.05	0.06	1.09	0.00	20.00
Granuloma	23	1.08	0.99	7.34	0.00	100.00
Peribiliar inflammation	12	0.56	0.63	4.01	0.00	40.00
Bile duct inflammation	0	0.00	0.00	0.00	0.00	0.00
Inflammation	1	0.05	0.03	0.61	0.00	11.11
Bile duct proliferation	37	1.73	1.68	8.46	0.00	80.00
Hepatocellular hypertrophy	20	0.94	0.82	4.27	0.00	40.00
Eosinophilic cytoplasm	0	0.00	0.00	0.00	0.00	0.00
Hepatocellular hyperplasia	1	0.05	0.01	0.23	0.00	4.17
Mixed cell foci	8	0.37	0.48	5.77	0.00	100.00
Fibrosis	2	0.09	0.06	0.77	0.00	10.00
Periportale inflammation infiltration	5	0.23	0.30	2.88	0.00	40.00
Hemopoiesis	25	1.17	1.34	6.90	0.00	60.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2143					
Malformation	0	0.00	0.00	0.00	0.00	0.00
Hepatodiaphragmatic herniation	1	0.05	0.03	0.55	0.00	10.00
Congestion	3	0.14	0.18	2.46	0.00	40.00
Hemorrhage	1	0.05	0.06	1.10	0.00	20.00
Glycogen deposition	277	12.93	15.16	33.32	0.00	100.00
Fatty change	560	26.13	27.47	33.52	0.00	100.00
Vacuolation	97	4.53	5.58	16.26	0.00	100.00
Sinusoidal dilation	0	0.00	0.00	0.00	0.00	0.00
Increased basophila	2	0.09	0.12	2.20	0.00	40.00
Hemopoietic cell foci	5	0.23	0.19	1.91	0.00	20.00
Erythropoiesis	191	8.91	9.73	19.39	0.00	120.00
Megakaryocytes	2	0.09	0.12	1.55	0.00	20.00
Pigment deposition	18	0.84	0.94	4.05	0.00	20.00
Hemosiderin	7	0.33	0.36	2.56	0.00	20.00
Necrosis	21	0.98	1.09	7.60	0.00	120.00
Hyaline inclusions	1	0.05	0.06	1.10	0.00	20.00
Cholestasis	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell foci	1275	59.50	61.30	34.35	0.00	160.00
Multinucleated giant cells	0	0.00	0.00	0.00	0.00	0.00
Single cell necrosis	68	3.17	3.82	14.42	0.00	100.00
Apoptosis	1	0.05	0.03	0.55	0.00	10.00
Granuloma	19	0.89	0.85	7.35	0.00	100.00
Peribiliar inflammation	4	0.19	0.24	4.40	0.00	80.00
Bile duct inflammation	1	0.05	0.06	1.10	0.00	20.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00
Bile duct proliferation	44	2.05	1.52	8.74	0.00	80.00
Hepatocellular hypertrophy	8	0.37	0.29	1.99	0.00	20.00
Eosinophilic cytoplasm	1	0.05	0.03	0.55	0.00	10.00
Hepatocellular hyperplasia	2	0.09	0.07	1.12	0.00	20.00
Mixed cell foci	7	0.33	0.36	4.66	0.00	80.00
Fibrosis	1	0.05	0.06	1.10	0.00	20.00
Periportale inflammation infiltration	3	0.14	0.18	2.46	0.00	40.00
Hemopoiesis	23	1.07	1.21	6.64	0.00	60.00

Oral cavity

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	5					
Parodontitis	5	100.00	100.00	0.00	100.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	5					
Parodontitis	5	100.00	100.00	0.00	100.00	100.00

Tongue

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	661					
Vascular mineralization	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	6	0.91	0.66	2.90	0.00	20.00
Inflammatory cell foci	1	0.15	0.12	1.10	0.00	10.00
Granuloma	1	0.15	0.12	1.10	0.00	10.00
Ulceration	0	0.00	0.00	0.00	0.00	0.00
Myofiber degeneration	1	0.15	0.12	1.10	0.00	10.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	721					
Vascular mineralization	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	13	1.80	1.07	5.80	0.00	40.00
Inflammatory cell foci	0	0.00	0.00	0.00	0.00	0.00
Granuloma	0	0.00	0.00	0.00	0.00	0.00
Ulceration	1	0.14	0.12	1.10	0.00	10.00
Myofiber degeneration	1	0.14	0.12	1.10	0.00	10.00

Esophagus

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	780					
Food in lumen	1	0.13	0.10	1.02	0.00	10.00
Dilation	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell foci	5	0.64	0.54	2.75	0.00	20.00
Abscess	1	0.13	1.03	10.15	0.00	100.00
Degeneration, muscle fibers	2	0.26	0.21	2.03	0.00	20.00
Hyperkeratosis	5	0.64	0.52	5.08	0.00	50.00
Fibrosis, muscular	1	0.13	0.10	1.02	0.00	10.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	814					
Food in lumen	0	0.00	0.00	0.00	0.00	0.00
Dilation	2	0.25	0.22	2.07	0.00	20.00
Mononuclear cell foci	2	0.25	0.22	2.07	0.00	20.00
Inflammatory cell foci	1	0.12	0.11	1.04	0.00	10.00
Abscess	0	0.00	0.00	0.00	0.00	0.00
Degeneration, muscle fibers	2	0.25	0.22	2.07	0.00	20.00
Hyperkeratosis	8	0.98	0.86	8.30	0.00	80.00
Fibrosis, muscular	1	0.12	0.11	1.04	0.00	10.00

Stomach

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1918					
Cyst	4	0.21	0.27	2.29	0.00	20.00
Squamous cyst	4	0.21	0.23	2.04	0.00	20.00
Squamous islets	4	0.21	0.13	1.41	0.00	20.00
Nonglandular stomach dilation	1	0.05	0.07	1.15	0.00	20.00
Dilated glands	42	2.19	2.66	8.66	0.00	40.00
Lymphoid follicles	23	1.20	1.34	5.62	0.00	40.00
Limiting ridge vacuolation	126	6.57	7.33	16.01	0.00	80.00
Fatty change	2	0.10	0.13	2.31	0.00	40.00
Forestomach ulceration	0	0.00	0.00	0.00	0.00	0.00
Congestion	20	1.04	1.10	5.33	0.00	40.00
Edema	18	0.94	1.10	7.69	0.00	100.00
Hyaline inclusions	338	17.62	19.34	35.97	0.00	100.00
Apoptotic bodies	1	0.05	0.07	1.15	0.00	20.00
Mineralization	2	0.10	0.10	1.29	0.00	20.00
Mononuclear cell foci	55	2.87	3.16	13.35	0.00	100.00
Inflammatory cell foci	173	9.02	10.20	21.79	0.00	100.00
Eosinophilic inflammatory infiltrate	29	1.51	1.83	9.92	0.00	80.00
Microabscess (es)	5	0.26	0.33	3.04	0.00	40.00
Arteritis / Periarteritis	1	0.05	0.07	1.15	0.00	20.00
Erosion: glandular stomach	27	1.41	1.54	6.35	0.00	60.00
Ulceration: forestomach	1	0.05	0.07	1.15	0.00	20.00
Ulceration	0	0.00	0.00	0.00	0.00	0.00
Epithelial degeneration	2	0.10	0.13	1.63	0.00	20.00
Focal spongiosis	1	0.05	0.07	1.15	0.00	20.00
Focal necrosis	2	0.10	0.10	1.29	0.00	20.00
Inflammation	24	1.25	1.30	7.83	0.00	80.00
Hyperkeratosis	42	2.19	2.76	12.19	0.00	100.00
Glandular vacuolation	0	0.00	0.00	0.00	0.00	0.00
Focal dyskeratosis	42	2.19	2.09	10.13	0.00	80.00
Serosal fibrosis	1	0.05	0.07	1.15	0.00	20.00
Epithelial atrophy	0	0.00	0.00	0.00	0.00	0.00
Parakeratosis	1	0.05	0.07	1.15	0.00	20.00
Epithelial hyperplasia	7	0.36	0.47	5.98	0.00	100.00
Basal cell hyperplasia	2	0.10	0.13	1.63	0.00	20.00
Mucosal dysplasia	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1953					
Cyst	8	0.41	0.43	5.92	0.00	100.00
Squamous cyst	3	0.15	0.11	1.31	0.00	20.00
Squamous islets	3	0.15	0.10	1.29	0.00	20.00
Nonglandular stomach dilation	1	0.05	0.07	1.16	0.00	20.00
Dilated glands	40	2.05	2.34	8.10	0.00	60.00
Lymphoid follicles	18	0.92	1.04	4.91	0.00	40.00
Limiting ridge vacuolation	150	7.68	9.16	21.46	0.00	100.00
Fatty change	1	0.05	0.07	1.16	0.00	20.00
Forestomach ulceration	1	0.05	0.33	5.78	0.00	100.00
Congestion	9	0.46	0.43	3.68	0.00	40.00
Edema	17	0.87	0.60	5.27	0.00	80.00
Hyaline inclusions	280	14.34	16.42	32.65	0.00	100.00
Apoptotic bodies	0	0.00	0.00	0.00	0.00	0.00
Mineralization	1	0.05	0.07	1.16	0.00	20.00
Mononuclear cell foci	43	2.20	2.37	10.78	0.00	80.00
Inflammatory cell foci	127	6.50	7.49	18.54	0.00	100.00
Eosinophilic inflammatory infiltrate	31	1.59	1.94	10.63	0.00	100.00
Microabscess (es)	6	0.31	0.27	2.83	0.00	40.00
Arteritis / Periarteritis	0	0.00	0.00	0.00	0.00	0.00
Erosion: glandular stomach	38	1.95	2.04	7.52	0.00	80.00
Ulceration: forestomach	2	0.10	0.13	1.63	0.00	20.00
Ulceration	1	0.05	0.07	1.16	0.00	20.00
Epithelial degeneration	0	0.00	0.00	0.00	0.00	0.00
Focal spongiosis	1	0.05	0.07	1.16	0.00	20.00
Focal necrosis	3	0.15	0.20	2.00	0.00	20.00
Inflammation	14	0.72	0.87	5.24	0.00	60.00
Hyperkeratosis	42	2.15	2.71	11.48	0.00	80.00
Glandular vacuolation	1	0.05	0.07	1.16	0.00	20.00
Focal dyskeratosis	30	1.54	1.61	9.45	0.00	100.00
Serosal fibrosis	2	0.10	0.13	1.63	0.00	20.00
Epithelial atrophy	1	0.05	0.07	1.16	0.00	20.00
Parakeratosis	1	0.05	0.07	1.16	0.00	20.00
Epithelial hyperplasia	12	0.61	0.77	6.64	0.00	100.00
Basal cell hyperplasia	4	0.20	0.23	2.64	0.00	40.00
Mucosal dysplasia	3	0.15	0.20	2.58	0.00	40.00

Forestomach

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	93					
Hyperplasia liniting ridge	9	9.68	9.29	20.18	0.00	60.00
Hyperkeratosis	10	10.75	12.14	18.47	0.00	60.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	83					
Hyperplasia liniting ridge	16	19.28	18.46	36.02	0.00	100.00
Hyperkeratosis	7	8.43	10.77	21.00	0.00	60.00

Glandular stomach

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	83					
Congestion	1	1.20	0.77	2.77	0.00	10.00
Glandular dilation	2	2.41	2.31	5.99	0.00	20.00
Inflammatory cell infiltration	10	12.05	7.69	27.74	0.00	100.00
Erosion	3	3.61	4.04	7.88	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	73					
Congestion	0	0.00	0.00	0.00	0.00	0.00
Glandular dilation	1	1.37	1.67	5.77	0.00	20.00
Inflammatory cell infiltration	1	1.37	0.83	2.89	0.00	10.00
Erosion	0	0.00	0.00	0.00	0.00	0.00

Duodenum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1839					
Dilation	0	0.00	0.00	0.00	0.00	0.00
Glandular dilation	1	0.05	0.03	0.59	0.00	10.00
Congestion	1	0.05	0.03	0.59	0.00	10.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Mucosal hyperplasia	1	0.05	0.07	1.18	0.00	20.00
Inflammatory cell infiltration	2	0.11	0.14	1.66	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1881					
Dilation	1	0.05	0.35	5.89	0.00	100.00
Glandular dilation	1	0.05	0.07	1.18	0.00	20.00
Congestion	1	0.05	0.03	0.59	0.00	10.00
Mononuclear cell foci	1	0.05	0.03	0.59	0.00	10.00
Mucosal hyperplasia	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell infiltration	2	0.11	0.14	2.36	0.00	40.00

Jejunum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1669					
Dilation	0	0.00	0.00	0.00	0.00	0.00
Congestion	6	0.36	0.34	2.81	0.00	30.00
Mineralization	57	3.42	4.22	12.05	0.00	60.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	167	10.01	12.49	29.96	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1705					
Dilation	1	0.06	0.38	6.18	0.00	100.00
Congestion	8	0.47	0.53	3.23	0.00	20.00
Mineralization	52	3.05	3.66	11.79	0.00	80.00
Mononuclear cell foci	1	0.06	0.08	1.24	0.00	20.00
Lymphoid hyperplasia	146	8.56	10.54	27.19	0.00	100.00

Ileum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1655					
Dilation	4	0.24	0.27	3.76	0.00	60.00
Congestion	10	0.60	0.80	7.73	0.00	100.00
Mineralization	6	0.36	0.46	3.48	0.00	40.00
Hemosiderin	1	0.06	0.10	1.55	0.00	25.00
Histiocytosis	1	0.06	0.08	1.24	0.00	20.00
Lymphoid hyperplasia	206	12.45	14.85	33.39	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1698					
Dilation	5	0.29	0.69	7.12	0.00	100.00
Congestion	14	0.82	0.81	5.68	0.00	70.00
Mineralization	6	0.35	0.46	5.26	0.00	80.00
Hemosiderin	0	0.00	0.00	0.00	0.00	0.00
Histiocytosis	1	0.06	0.08	1.24	0.00	20.00
Lymphoid hyperplasia	183	10.78	13.17	31.05	0.00	100.00

Peyer's patches NOS

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	739					
Mineralization	10	1.35	1.42	5.60	0.00	40.00
Fatty change	2	0.27	0.31	2.50	0.00	20.00
Lymphoid hyperplasia	70	9.47	8.42	26.68	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	738					
Mineralization	11	1.49	1.50	6.68	0.00	40.00
Fatty change	2	0.27	0.31	2.50	0.00	20.00
Lymphoid hyperplasia	67	9.08	8.19	26.44	0.00	100.00

Peper's patches - jejunum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	687					
Mineralization	62	9.02	8.98	15.53	0.00	75.00
Fatty change	3	0.44	0.53	5.64	0.00	60.00
Inflammatory cell foci	1	0.15	0.18	1.88	0.00	20.00
Lymphoid hyperplasia	244	35.52	39.29	37.85	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	639					
Mineralization	44	6.89	5.97	13.99	0.00	80.00
Fatty change	2	0.31	0.00	0.00	0.00	0.00
Inflammatory cell foci	1	0.16	0.18	1.91	0.00	20.00
Lymphoid hyperplasia	189	29.58	31.57	34.97	0.00	100.00

Peper's patches - ileum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	709					
Dilation	0	0.00	0.00	0.00	0.00	0.00
Fatty change	0	0.00	0.00	0.00	0.00	0.00
Mineralization	12	1.69	1.33	8.85	0.00	88.89
Lymphoid hyperplasia	365	51.48	54.78	45.29	0.00	100.00
Inflammatory cell infiltration	2	0.28	0.36	3.78	0.00	40.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	681					
Dilation	1	0.15	0.18	1.91	0.00	20.00
Fatty change	1	0.15	0.00	0.00	0.00	0.00
Mineralization	12	1.76	1.25	8.99	0.00	90.00
Lymphoid hyperplasia	338	49.63	53.41	44.94	0.00	100.00
Inflammatory cell infiltration	0	0.00	0.00	0.00	0.00	0.00

Caecum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1827					
Dilation	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	0	0.00	0.00	0.00	0.00	0.00
Congestion	4	0.22	0.21	2.64	0.00	40.00
Nematodes	2	0.11	0.07	0.83	0.00	10.00
Mononuclear cell infiltration	11	0.60	0.49	5.40	0.00	80.00
Edema	2	0.11	0.19	2.29	0.00	33.33
Inflammation cell infiltration	6	0.33	0.28	2.49	0.00	30.00
Erosion	1	0.05	0.07	1.18	0.00	20.00
Inflammation	3	0.16	0.21	3.54	0.00	60.00
Mucosal hyperplasia	1	0.05	0.03	0.59	0.00	10.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1869					
Dilation	1	0.05	0.35	5.91	0.00	100.00
Lymphoid hyperplasia	1	0.05	0.07	1.18	0.00	20.00
Congestion	3	0.16	0.21	3.55	0.00	60.00
Nematodes	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell infiltration	6	0.32	0.38	4.91	0.00	80.00
Edema	5	0.27	0.38	4.61	0.00	60.00
Inflammation cell infiltration	3	0.16	0.17	1.77	0.00	20.00
Erosion	0	0.00	0.00	0.00	0.00	0.00
Inflammation	2	0.11	0.14	2.37	0.00	40.00
Mucosal hyperplasia	1	0.05	0.03	0.59	0.00	10.00

Colon

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1824					
Dilation	31	1.70	2.06	9.64	0.00	80.00
Nematodes	4	0.22	0.17	1.56	0.00	20.00
Mononuclear cell foci	1	0.05	0.07	1.18	0.00	20.00
Submucosal edema	1	0.05	0.07	1.18	0.00	20.00
Lymphoid hyperplasia	2	0.11	0.14	1.67	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1862					
Dilation	26	1.40	1.73	8.71	0.00	80.00
Nematodes	3	0.16	0.11	1.02	0.00	10.00
Mononuclear cell foci	1	0.05	0.07	1.19	0.00	20.00
Submucosal edema	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	2	0.11	0.14	1.68	0.00	20.00

Rectum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1829					
Nematodes	11	0.60	0.46	2.92	0.00	30.00
Dilation	34	1.86	2.11	7.50	0.00	60.00
Mononuclear cell foci	5	0.27	0.35	3.52	0.00	40.00
Edema	0	0.00	0.00	0.00	0.00	0.00
Inflammation	1	0.05	0.07	1.18	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1864					
Nematodes	4	0.21	0.24	2.11	0.00	20.00
Dilation	50	2.68	3.26	10.04	0.00	60.00
Mononuclear cell foci	1	0.05	0.07	1.18	0.00	20.00
Edema	5	0.27	0.21	1.85	0.00	20.00
Inflammation	4	0.21	0.24	2.11	0.00	20.00

Salivary glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	735					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	784					

Parotid salivary glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	212					
Ectopic salivary gland	10	4.72	3.22	7.89	0.00	30.00
Ectopic pancreas	0	0.00	0.00	0.00	0.00	0.00
Lipidosis	4	1.89	1.82	5.88	0.00	20.00
Acinar vacuolation	0	0.00	0.00	0.00	0.00	0.00
Mineralization	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	2	0.94	0.38	1.78	0.00	8.33
Mixed cell infiltration	1	0.47	0.91	4.26	0.00	20.00
Inflammation	2	0.94	0.64	2.27	0.00	10.00
Atrophy	10	4.72	4.28	19.17	0.00	90.00
Basophilic acini	17	8.02	5.30	16.12	0.00	70.00
Acinar hypertrophy, diffuse	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	202					
Ectopic salivary gland	4	1.98	1.63	4.81	0.00	20.00
Ectopic pancreas	1	0.50	0.48	2.18	0.00	10.00
Lipidosis	0	0.00	0.00	0.00	0.00	0.00
Acinar vacuolation	1	0.50	0.95	4.36	0.00	20.00
Mineralization	1	0.50	0.48	2.18	0.00	10.00
Mononuclear cell foci	2	0.99	0.40	1.82	0.00	8.33
Mixed cell infiltration	1	0.50	0.95	4.36	0.00	20.00
Inflammation	1	0.50	0.48	2.18	0.00	10.00
Atrophy	7	3.47	3.10	13.08	0.00	60.00
Basophilic acini	20	9.90	5.60	14.40	0.00	50.00
Acinar hypertrophy, diffuse	2	0.99	0.67	2.32	0.00	10.00

Submandibular salivary glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	809					
Acinar vacuolation	1	0.12	0.20	1.99	0.00	20.00
Fatty Atrophy	5	0.62	0.50	4.98	0.00	50.00
Acinar atrophy	0	0.00	0.00	0.00	0.00	0.00
Acinar hypertrophy	0	0.00	0.00	0.00	0.00	0.00
Ductular glands	2	0.25	0.40	3.98	0.00	40.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	849					
Acinar vacuolation	0	0.00	0.00	0.00	0.00	0.00
Fatty Atrophy	0	0.00	0.00	0.00	0.00	0.00
Acinar atrophy	2	0.24	0.08	0.84	0.00	8.33
Acinar hypertrophy	1	0.12	0.04	0.42	0.00	4.17
Ductular glands	0	0.00	0.00	0.00	0.00	0.00

Sublingual salivary glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	824					
Ectopic parotid	1	0.12	0.10	0.99	0.00	10.00
Mononuclear cell foci	1	0.12	0.10	0.99	0.00	10.00
Glandular atrophy	1	0.12	0.10	0.99	0.00	10.00
Degeneration	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	864					
Ectopic parotid	1	0.12	0.10	1.00	0.00	10.00
Mononuclear cell foci	1	0.12	0.04	0.41	0.00	4.17
Glandular atrophy	0	0.00	0.00	0.00	0.00	0.00
Degeneration	1	0.12	0.10	1.00	0.00	10.00

Urinary bladder

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1838					
Distension	19	1.03	1.45	8.92	0.00	100.00
Congestion	7	0.38	0.66	6.95	0.00	100.00
Proteinaceous cast	4	0.22	0.21	1.85	0.00	20.00
Edema	0	0.00	0.00	0.00	0.00	0.00
Osseus metaplasia	1	0.05	0.07	1.17	0.00	20.00
Urolithiasis	2	0.11	0.07	0.83	0.00	10.00
Mononuclear cell foci	15	0.82	1.17	7.35	0.00	100.00
Inflammatory cell foci	1	0.05	0.07	1.17	0.00	20.00
Inflammation	3	0.16	0.17	1.76	0.00	20.00
Ectasia	2	0.11	0.07	0.83	0.00	10.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1879					
Distension	9	0.48	0.91	6.73	0.00	100.00
Congestion	0	0.00	0.00	0.00	0.00	0.00
Proteinaceous cast	0	0.00	0.00	0.00	0.00	0.00
Edema	1	0.05	0.07	1.18	0.00	20.00
Osseus metaplasia	0	0.00	0.00	0.00	0.00	0.00
Urolithiasis	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	9	0.48	0.52	3.03	0.00	20.00
Inflammatory cell foci	0	0.00	0.00	0.00	0.00	0.00
Inflammation	1	0.05	0.07	1.18	0.00	20.00
Ectasia	0	0.00	0.00	0.00	0.00	0.00

Ureter

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	130					
Dilation	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	130					
Dilation	1	0.77	0.77	2.77	0.00	10.00

Kidneys

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2160					
Pelvic dilation	182	8.43	8.67	15.08	0.00	80.00
Hydronephrosis	12	0.56	0.60	5.30	0.00	80.00
Cyst(s)	4	0.19	0.15	1.45	0.00	20.00
Medullary cyst(s)	1	0.05	0.06	1.10	0.00	20.00
Tubular cyst	3	0.14	0.15	1.64	0.00	20.00
Distended papillary duct	0	0.00	0.00	0.00	0.00	0.00
Urothelial vesicles	3	0.14	0.18	2.46	0.00	40.00
Hyaline droplets	1288	59.63	61.16	39.57	0.00	100.00
Lipofuscin pigment	0	0.00	0.00	0.00	0.00	0.00
Intratubular pigment	0	0.00	0.00	0.00	0.00	0.00
Mineralization	33	1.53	1.65	6.40	0.00	40.00
Papillary mineralization	5	0.23	0.24	2.05	0.00	20.00
Corticomedullary mineralization	91	4.21	4.28	10.78	0.00	60.00
Pelvic mineralization	14	0.65	0.54	3.61	0.00	40.00
Hemorrhage	14	0.65	0.82	7.84	0.00	100.00
Glomerulosclerosis	1	0.05	0.03	0.55	0.00	10.00
Tubular dilation	14	0.65	0.57	3.89	0.00	50.00
Vacuolated cytoplasm	20	0.93	0.88	5.89	0.00	60.00
Cuboidal metaplasia, glomerulosa	1	0.05	0.06	1.10	0.00	20.00
Tubular cast(s)	53	2.45	2.61	9.71	0.00	80.00
Granular casts	5	0.23	0.30	5.50	0.00	100.00
Tubular basophilia	675	31.25	31.67	27.26	0.00	100.00
Diffuse basophilia	3	0.14	0.18	3.30	0.00	60.00
Tubular degeneration	24	1.11	1.20	6.50	0.00	60.00
Tubular atrophy	2	0.09	0.12	2.20	0.00	40.00
Tubular necrosis	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	417	19.31	19.20	25.55	0.00	100.00
Interstitial inflammation	18	0.83	0.65	3.89	0.00	40.00
Pyelitis	21	0.97	0.89	5.29	0.00	60.00
Pyelonephritis	1	0.05	0.03	0.46	0.00	8.33
Papillary necrosis	1	0.05	0.03	0.46	0.00	8.33
Granuloma	2	0.09	0.06	0.78	0.00	10.00
Inflammation	17	0.79	0.78	5.21	0.00	60.00
Scarring	2	0.09	0.09	1.23	0.00	20.00
Fibrosis	4	0.19	0.21	1.97	0.00	20.00
Interstitial cell proliferation	1	0.05	0.03	0.55	0.00	10.00
Basophilic focus	2	0.09	0.12	1.55	0.00	20.00
Urothelial hyperplasia	19	0.88	0.79	4.26	0.00	50.00
Brownish pigment	0	0.00	0.00	0.00	0.00	0.00
Congestion	5	0.23	0.27	2.74	0.00	40.00
Tubular swelling	2	0.09	0.06	1.10	0.00	20.00
Inflammatory cell foci	3	0.14	0.12	1.55	0.00	20.00
Arteritis / Periarteritis	1	0.05	0.03	0.55	0.00	10.00
Tubular hyperplasia	1	0.05	0.06	1.10	0.00	20.00
Interstitial inflammatory cell foci	2	0.09	0.06	1.10	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2178					
Pelvic dilation	122	5.60	5.53	12.12	0.00	60.00
Hydronephrosis	7	0.32	0.37	3.01	0.00	40.00
Cyst(s)	5	0.23	0.31	2.46	0.00	20.00
Medullary cyst(s)	0	0.00	0.00	0.00	0.00	0.00
Tubular cyst	2	0.09	0.09	1.24	0.00	20.00
Distended papillary duct	0	0.00	0.00	0.00	0.00	0.00
Urothelial vesicles	1	0.05	0.06	1.11	0.00	20.00
Hyaline droplets	7	0.32	0.39	4.14	0.00	66.67
Lipofuscin pigment	23	1.06	0.60	5.84	0.00	75.00
Intratubular pigment	10	0.46	0.43	4.81	0.00	60.00
Mineralization	208	9.55	9.66	26.10	0.00	100.00
Papillary mineralization	6	0.28	0.34	2.52	0.00	20.00
Corticomedullary mineralization	831	38.15	39.46	39.77	0.00	100.00
Pelvic mineralization	19	0.87	0.84	5.45	0.00	60.00
Hemorrhage	10	0.46	0.61	6.62	0.00	100.00
Glomerulosclerosis	0	0.00	0.00	0.00	0.00	0.00
Tubular dilation	14	0.64	0.67	4.16	0.00	40.00
Vacuolated cytoplasm	57	2.62	3.39	15.85	0.00	100.00
Cuboidal metaplasia, glomerulosa	0	0.00	0.00	0.00	0.00	0.00
Tubular cast(s)	49	2.25	2.02	9.85	0.00	80.00
Granular casts	6	0.28	0.37	5.64	0.00	100.00
Tubular basophilia	706	32.42	34.29	31.72	0.00	100.00
Diffuse basophilia	7	0.32	0.43	5.52	0.00	80.00
Tubular degeneration	27	1.24	1.51	8.32	0.00	100.00
Tubular atrophy	1	0.05	0.06	1.11	0.00	20.00
Tubular necrosis	1	0.05	0.03	0.55	0.00	10.00
Mononuclear cell foci	322	14.78	15.45	24.08	0.00	100.00
Interstitial inflammation	24	1.10	0.81	4.43	0.00	40.00
Pyelitis	15	0.69	0.55	3.69	0.00	40.00
Pyelonephritis	0	0.00	0.00	0.00	0.00	0.00
Papillary necrosis	0	0.00	0.00	0.00	0.00	0.00
Granuloma	0	0.00	0.00	0.00	0.00	0.00
Inflammation	13	0.60	0.58	4.50	0.00	60.00
Scarring	2	0.09	0.12	2.21	0.00	40.00
Fibrosis	26	1.19	1.38	7.93	0.00	80.00
Interstitial cell proliferation	1	0.05	0.03	0.55	0.00	10.00
Basophilic focus	6	0.28	0.37	5.64	0.00	100.00
Urothelial hyperplasia	7	0.32	0.32	2.34	0.00	20.00
Brownish pigment	1	0.05	0.06	1.11	0.00	20.00
Congestion	1	0.05	0.06	1.11	0.00	20.00
Tubular swelling	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell foci	0	0.00	0.00	0.00	0.00	0.00
Arteritis / Periarteritis	0	0.00	0.00	0.00	0.00	0.00
Tubular hyperplasia	10	0.46	0.34	4.59	0.00	80.00
Interstitial inflammatory cell foci	0	0.00	0.00	0.00	0.00	0.00

Skin

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	834					
Congestion	1	0.12	0.91	9.53	0.00	100.00
Hemorrhage	1	0.12	0.05	0.48	0.00	5.00
Mononuclear cell foci	7	0.84	0.73	3.51	0.00	20.00
Inflammatory cell infiltration	1	0.12	0.09	0.95	0.00	10.00
Scab formation	3	0.36	0.73	5.20	0.00	50.00
Necrosis	1	0.12	0.91	9.53	0.00	100.00
Abscess	1	0.12	0.09	0.95	0.00	10.00
Ulceration	2	0.24	0.64	5.12	0.00	50.00
Folliculitis	1	0.12	0.18	1.91	0.00	20.00
Inflammation	5	0.60	2.09	13.48	0.00	100.00
Fibrosis	1	0.12	0.18	1.91	0.00	20.00
Epithelial hyperplasia	2	0.24	0.64	5.12	0.00	50.00
Atrophy	1	0.12	0.05	0.48	0.00	5.00
Hyperkeratosis	0	0.00	0.00	0.00	0.00	0.00
Acanthosis	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell foci	4	0.48	1.12	6.82	0.00	50.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	899					
Congestion	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	4	0.44	0.37	1.91	0.00	10.00
Inflammatory cell infiltration	1	0.11	0.09	0.97	0.00	10.00
Scab formation	1	0.11	0.19	1.93	0.00	20.00
Necrosis	0	0.00	0.00	0.00	0.00	0.00
Abscess	0	0.00	0.00	0.00	0.00	0.00
Ulceration	1	0.11	0.09	0.97	0.00	10.00
Folliculitis	1	0.11	0.00	0.00	0.00	0.00
Inflammation	4	0.44	0.37	3.05	0.00	30.00
Fibrosis	2	0.22	0.19	1.36	0.00	10.00
Epithelial hyperplasia	6	0.67	0.65	3.70	0.00	30.00
Atrophy	2	0.22	0.33	2.59	0.00	25.00
Hyperkeratosis	2	0.22	0.33	2.59	0.00	25.00
Acanthosis	1	0.11	0.23	2.42	0.00	25.00
Inflammatory cell foci	4	0.44	0.50	3.74	0.00	33.33

Mammary gland

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	807					
Secretion	7	0.87	0.70	5.37	0.00	50.00
Glandular proliferation	10	1.24	1.00	10.00	0.00	100.00
Vacuolation	1	0.12	0.11	1.11	0.00	11.11
Mononuclear cell foci	1	0.12	0.25	2.50	0.00	25.00
Granuloma	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	1	0.12	0.10	1.00	0.00	10.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	844					
Secretion	17	2.01	1.24	9.38	0.00	90.00
Glandular proliferation	21	2.49	2.16	14.31	0.00	100.00
Vacuolation	1	0.12	0.05	0.51	0.00	5.00
Mononuclear cell foci	1	0.12	0.10	1.02	0.00	10.00
Granuloma	1	0.12	0.10	1.02	0.00	10.00
Lymphoid hyperplasia	2	0.24	0.41	4.06	0.00	40.00

Testes

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2077					
Immature	1	0.05	0.06	1.12	0.00	20.00
Hypoplastic tubules	1	0.05	0.06	1.12	0.00	20.00
Cellular debris	11	0.53	0.28	2.79	0.00	40.00
Congestion	1	0.05	0.03	0.56	0.00	10.00
Sertoli cell vacuolation	112	5.39	6.22	19.76	0.00	100.00
Hypospermatogenesis	2	0.10	0.09	1.25	0.00	20.00
Interstitial edema	4	0.19	0.19	2.37	0.00	40.00
Apoptosis	5	0.24	0.28	2.79	0.00	40.00
Sperm stasis	3	0.14	0.13	1.58	0.00	20.00
Tubular degeneration	83	4.00	4.22	10.03	0.00	100.00
Edema	1	0.05	0.03	0.56	0.00	10.00
Giant spermatidic cells	19	0.91	0.98	4.76	0.00	40.00
Mononuclear cell foci	5	0.24	0.31	2.48	0.00	20.00
Spermatid retention	2	0.10	0.09	1.25	0.00	20.00
Leydig cell hyperplasia	2	0.10	0.13	1.58	0.00	20.00

Epididymides

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1933					
Sperm stasis	1	0.05	0.03	0.57	0.00	10.00
Oligospermia	6	0.31	0.36	2.59	0.00	20.00
Aspermia	5	0.26	0.23	1.88	0.00	20.00
Cellular debris	6	0.31	0.32	2.40	0.00	20.00
Epithelial vacuolation	21	1.09	1.36	7.53	0.00	60.00
Interstitial edema	1	0.05	0.03	0.57	0.00	10.00
Mononuclear cell foci	150	7.76	7.67	19.59	0.00	100.00
Mixed cell infiltration	4	0.21	0.13	2.28	0.00	40.00
Sperm granuloma	6	0.31	0.88	8.28	0.00	100.00
Peritonitis	1	0.05	0.05	0.95	0.00	16.67
Inflammation	2	0.10	0.39	5.81	0.00	100.00
Capsular inflammation	2	0.10	0.11	1.90	0.00	33.33
Atrophy	2	0.10	0.10	1.27	0.00	20.00
Epithelial hypertrophy	1	0.05	0.06	1.14	0.00	20.00
Intratubular cell debris	1	0.05	0.06	1.14	0.00	20.00

Prostate

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1888					
Glandular dilation	5	0.26	0.34	5.83	0.00	100.00
Changed colloid	1	0.05	0.07	1.17	0.00	20.00
Concrements	4	0.21	0.24	2.67	0.00	40.00
Hemorrhage	2	0.11	0.14	1.65	0.00	20.00
Mononuclear cell foci	46	2.44	2.41	8.38	0.00	60.00
Inflammatory cell foci	16	0.85	0.68	3.63	0.00	30.00
Inflammation	53	2.81	2.30	6.65	0.00	40.00
Glandular atrophy	8	0.42	0.31	2.08	0.00	20.00
Focal hyperplasia	3	0.16	0.14	1.65	0.00	20.00

Coagulating glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	973					
Immature	1	0.10	0.14	1.65	0.00	20.00
Mononuclear cell foci	2	0.21	0.27	3.30	0.00	40.00
Inflammation	1	0.10	0.07	0.82	0.00	10.00
Atrophy	2	0.21	0.14	1.16	0.00	10.00

Seminal vesicles

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1782					
Immature	1	0.06	0.07	1.17	0.00	20.00
Reduced colloid	10	0.56	1.43	10.82	0.00	100.00
Congestion	33	1.85	5.03	20.08	0.00	100.00
Hemorrhage	4	0.22	0.24	2.10	0.00	20.00
Mononuclear cell foci	2	0.11	0.14	1.65	0.00	20.00
Inflammatory cell foci	1	0.06	0.07	1.17	0.00	20.00
Atrophy	6	0.34	0.20	1.64	0.00	20.00

Ovaries

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2001					
Congestion	16	0.80	1.14	7.21	0.00	100.00
Corpus rubra	1	0.05	0.03	0.57	0.00	10.00
Atretic follicles	56	2.80	0.28	4.01	0.00	67.50
Embryonic remnant	5	0.25	0.36	4.44	0.00	60.00
Tubular dilatation	12	0.60	0.62	5.47	0.00	60.00
Bursa dilation	15	0.75	0.86	6.65	0.00	100.00
Follicular cyst	8	0.40	0.29	3.64	0.00	60.00
Cyst(s), luteal	10	0.50	0.34	4.19	0.00	70.00
Cyst	2	0.10	0.10	1.27	0.00	20.00
Hemorrhage	11	0.55	0.39	4.76	0.00	80.00
Hemosiderin	1	0.05	0.06	1.14	0.00	20.00
Pigment	1	0.05	0.03	0.57	0.00	10.00
Hemopoietic cell foci	3	0.15	0.16	2.35	0.00	40.00
Mononuclear cell foci	1	0.05	0.06	1.14	0.00	20.00
Inflammation, oviduct	1	0.05	0.03	0.57	0.00	10.00
Interstitial cell vacuolation	1	0.05	0.03	0.57	0.00	10.00
Atrophy	1	0.05	0.06	1.14	0.00	20.00
Hypertrophic corpora lutea	26	1.30	0.39	5.81	0.00	100.00
Interstitial cell hyperplasia	12	0.60	0.49	5.48	0.00	90.00

Oviducts

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	40					
Luminal detritus	1	2.50	2.00	4.47	0.00	10.00
Cystic oviduct	1	2.50	0.00	0.00	0.00	0.00

Uterus

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1904					
Cornual dilation	219	11.50	14.32	24.60	0.00	100.00
Hydrometra	17	0.89	1.14	6.77	0.00	60.00
Estrus/Proestrus	54	2.84	3.14	13.36	0.00	100.00
Metestrus	32	1.68	1.69	8.48	0.00	80.00
Diestrus	33	1.73	1.74	8.43	0.00	60.00
Congestion	11	0.58	0.57	3.67	0.00	40.00
Cyst	2	0.11	0.13	1.64	0.00	20.00
Squamous cyst	3	0.16	0.17	1.73	0.00	20.00
Atrophy	1	0.05	0.07	1.16	0.00	20.00
Squamous hyperplasia	1	0.05	0.00	0.07	0.00	1.25
Stromal edema	1	0.05	0.07	1.16	0.00	20.00
Metaplasia squamous	2	0.11	0.07	0.82	0.00	10.00
Hyperplasia endometrial stromal	5	0.26	0.17	2.90	0.00	50.00
Necrosis single cell	1	0.05	0.03	0.58	0.00	10.00
Oedema endometrial stroma	1	0.05	0.03	0.58	0.00	10.00
Mononuclear cell infiltrate	2	0.11	0.10	1.29	0.00	20.00
Decidual alteration	2	0.11	0.07	1.16	0.00	20.00

Cervix

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	111					

Vagina

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1919					
Malformation	1	0.05	0.07	1.17	0.00	20.00
Lumen dilation	1	0.05	0.07	1.17	0.00	20.00
Proestrus	248	12.92	11.72	16.84	0.00	60.00
Estrus	219	11.41	10.69	17.38	0.00	80.00
Metestrus	268	13.97	12.95	18.88	0.00	100.00
Diestrus	253	13.18	12.66	19.02	0.00	100.00
Anestrus	9	0.47	0.31	3.35	0.00	50.00
Mucification	17	0.89	0.75	4.98	0.00	40.00
Mononuclear cell foci	4	0.21	0.08	1.19	0.00	20.00
Mucosal cystic degeneration	1	0.05	0.03	0.58	0.00	10.00
Epithelial sloughing	5	0.26	0.17	2.92	0.00	50.00
Secretion	4	0.21	0.14	2.34	0.00	40.00
Mucosa atrophy	1	0.05	0.03	0.58	0.00	10.00
Keratinisation	7	0.36	0.34	3.08	0.00	40.00

Bone marrow

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1540					
Increased myelopoiesis	15	0.97	0.68	6.72	0.00	100.00
Increased erythropoiesis	4	0.26	0.32	2.52	0.00	20.00
Decreased erythropoiesis	5	0.32	0.32	2.35	0.00	20.00
Fatty replacement	102	6.62	6.67	21.58	0.00	100.00
Hemosiderin	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1580					
Increased myelopoiesis	5	0.32	0.36	4.07	0.00	60.00
Increased erythropoiesis	3	0.19	0.20	1.90	0.00	20.00
Decreased erythropoiesis	4	0.25	0.32	4.02	0.00	60.00
Fatty replacement	122	7.72	8.38	23.44	0.00	100.00
Hemosiderin	1	0.06	0.08	1.27	0.00	20.00

Bone marrow - sternum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	596					
Fatty replacement	17	2.85	1.73	9.80	0.00	65.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	657					
Fatty replacement	26	3.96	3.10	14.39	0.00	80.00

Bone marrow - femur

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1724					
Increased myelopoiesis	4	0.23	0.24	2.10	0.00	25.00
Increased erythropoiesis	4	0.23	0.27	2.34	0.00	25.00
Decreased erythropoiesis	1	0.06	0.04	0.60	0.00	10.00
Fatty replacement	169	9.80	9.13	24.15	0.00	100.00
Hemosiderin	0	0.00	0.00	0.00	0.00	0.00
Inflammation	2	0.12	0.07	1.21	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1755					
Increased myelopoiesis	1	0.06	0.04	0.61	0.00	10.00
Increased erythropoiesis	3	0.17	0.18	1.81	0.00	20.00
Decreased erythropoiesis	0	0.00	0.00	0.00	0.00	0.00
Fatty replacement	179	10.20	10.09	24.04	0.00	100.00
Hemosiderin	1	0.06	0.07	1.21	0.00	20.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Mesenteric lymph nodes

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1917					
Congestion	2	0.10	0.07	0.82	0.00	10.00
Erythrophagocytosis/Congestion	5	0.26	0.30	3.70	0.00	60.00
Hemorrhage	3	0.16	0.17	1.73	0.00	20.00
Sinus dilation	8	0.42	0.47	4.39	0.00	60.00
Hemosiderin	2	0.10	0.13	2.31	0.00	40.00
Pigment deposits	7	0.37	0.30	3.31	0.00	40.00
Granulopoiesis	2	0.10	0.13	1.63	0.00	20.00
Histiocytosis	143	7.46	8.39	24.65	0.00	120.00
Histiocytic agglomeration	5	0.26	0.33	3.05	0.00	40.00
Mastocytosis	24	1.25	1.61	9.97	0.00	100.00
Sinusoidal plasma cells	6	0.31	0.40	4.90	0.00	60.00
Increased eosinophils	2	0.10	0.13	2.31	0.00	40.00
Lymphoid hyperplasia	829	43.24	42.09	43.38	0.00	100.00
Fat vacuoles	1	0.05	0.07	1.16	0.00	20.00
Lymphoid depletion	3	0.16	0.10	1.29	0.00	20.00
Germinal centres	46	2.40	2.41	14.91	0.00	100.00
Mast cell hyperplasia	1	0.05	0.07	1.16	0.00	20.00
Apoptosis	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1942					
Congestion	2	0.10	0.37	5.83	0.00	100.00
Erythrophagocytosis/Congestion	6	0.31	0.40	4.92	0.00	80.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Sinus dilation	8	0.41	0.54	5.90	0.00	80.00
Hemosiderin	2	0.10	0.13	1.64	0.00	20.00
Pigment deposits	5	0.26	0.24	2.65	0.00	40.00
Granulopoiesis	0	0.00	0.00	0.00	0.00	0.00
Histiocytosis	146	7.52	8.57	25.28	0.00	140.00
Histiocytic agglomeration	3	0.15	0.13	1.64	0.00	20.00
Mastocytosis	17	0.88	1.14	8.06	0.00	100.00
Sinusoidal plasma cells	0	0.00	0.00	0.00	0.00	0.00
Increased eosinophils	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	802	41.30	44.77	70.39	0.00	1000.00
Fat vacuoles	1	0.05	0.07	1.16	0.00	20.00
Lymphoid depletion	3	0.15	0.17	1.74	0.00	20.00
Germinal centres	45	2.32	2.46	14.92	0.00	100.00
Mast cell hyperplasia	1	0.05	0.07	1.16	0.00	20.00
Apoptosis	1	0.05	0.07	1.16	0.00	20.00

Mandibular lymph nodes

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1842					
Congestion	16	0.87	1.44	9.58	0.00	100.00
Erythrophagocytosis/Congestion	5	0.27	0.46	6.04	0.00	100.00
Hemorrhage	3	0.16	0.21	2.02	0.00	20.00
Sinusoidal dilation	3	0.16	0.21	2.62	0.00	40.00
Plasmacytosis	592	32.14	29.93	38.91	0.00	100.00
Histiocytosis	57	3.09	3.26	14.46	0.00	100.00
Lymphoid hyperplasia	788	42.78	42.88	42.27	0.00	100.00
Mastocytosis	1	0.05	0.07	1.17	0.00	20.00
Hemosiderin	4	0.22	0.19	1.77	0.00	20.00
Tattoo ink	0	0.00	0.00	0.00	0.00	0.00
Pigment deposition	4	0.22	0.17	2.11	0.00	30.00
Interstitial edema	1	0.05	0.03	0.59	0.00	10.00
Sinusoidal mast cells	0	0.00	0.00	0.00	0.00	0.00
Lymphoid atrophy	3	0.16	0.14	1.66	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1891					
Congestion	13	0.69	1.72	11.13	0.00	100.00
Erythrophagocytosis/Congestion	8	0.42	0.33	2.50	0.00	20.00
Hemorrhage	8	0.42	0.72	6.73	0.00	100.00
Sinusoidal dilation	0	0.00	0.00	0.00	0.00	0.00
Plasmacytosis	639	33.79	32.55	41.67	0.00	100.00
Histiocytosis	81	4.28	4.79	18.36	0.00	100.00
Lymphoid hyperplasia	796	42.09	43.62	42.68	0.00	100.00
Mastocytosis	3	0.16	0.21	2.02	0.00	20.00
Hemosiderin	4	0.21	0.21	2.02	0.00	20.00
Tattoo ink	1	0.05	0.07	1.17	0.00	20.00
Pigment deposition	8	0.42	0.34	4.22	0.00	60.00
Interstitial edema	0	0.00	0.00	0.00	0.00	0.00
Sinusoidal mast cells	1	0.05	0.07	1.17	0.00	20.00
Lymphoid atrophy	0	0.00	0.00	0.00	0.00	0.00

Mediastinal lymph nodes

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	167					
Congestion	2	1.20	7.86	26.65	0.00	100.00
Histiocytosis	0	0.00	0.00	0.00	0.00	0.00
Plasmacytosis	4	2.40	2.86	10.69	0.00	40.00
Hemosiderin	6	3.59	2.50	5.10	0.00	15.00
Pigment	0	0.00	0.00	0.00	0.00	0.00
Lymphoid atrophy	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	50	29.94	23.57	20.52	0.00	50.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	171					
Congestion	10	5.85	10.36	26.49	0.00	100.00
Histiocytosis	7	4.09	5.00	18.71	0.00	70.00
Plasmacytosis	2	1.17	1.43	5.35	0.00	20.00
Hemosiderin	88	51.46	45.12	32.31	0.00	85.00
Pigment	9	5.26	8.57	21.79	0.00	60.00
Lymphoid atrophy	2	1.17	1.43	5.35	0.00	20.00
Lymphoid hyperplasia	59	34.50	32.98	23.79	0.00	83.33

Other lymph nodes

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	245					
Congestion	7	2.86	10.61	29.15	0.00	100.00
Sinusoidal dilation	4	1.63	8.18	25.43	0.00	100.00
Histocytosis	1	0.41	0.13	0.76	0.00	4.35
Plasmacytosis	7	2.86	2.29	9.19	0.00	40.00
Hemosiderin	5	2.04	5.26	19.19	0.00	100.00
Pigment	0	0.00	0.00	0.00	0.00	0.00
Inflammation	2	0.82	0.43	2.49	0.00	14.29
Capsular fibrosis	2	0.82	0.43	2.49	0.00	14.29
Lymphoid hyperplasia	44	17.96	16.04	26.65	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	220					
Congestion	7	3.18	9.76	27.25	0.00	100.00
Sinusoidal dilation	0	0.00	0.00	0.00	0.00	0.00
Histocytosis	0	0.00	0.00	0.00	0.00	0.00
Plasmacytosis	4	1.82	1.54	5.66	0.00	23.08
Hemosiderin	12	5.45	2.70	7.22	0.00	29.17
Pigment	2	0.91	0.55	2.91	0.00	15.38
Inflammation	0	0.00	0.00	0.00	0.00	0.00
Capsular fibrosis	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	44	20.00	19.33	29.49	0.00	100.00

Thymus

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1954					
Cyst(s)	175	8.96	9.29	14.98	0.00	80.00
Congestion	40	2.05	2.48	10.96	0.00	100.00
Erythrophagocytosis	1	0.05	0.06	1.13	0.00	20.00
Hemorrhage	53	2.71	3.39	11.21	0.00	100.00
Histiocytosis	59	3.02	2.48	12.70	0.00	100.00
Inflammatory cell foci	0	0.00	0.00	0.00	0.00	0.00
Hemosiderosis	0	0.00	0.00	0.00	0.00	0.00
Atrophy	234	11.98	11.01	23.32	0.00	100.00
Hyperplastic epithelium	5	0.26	0.16	2.84	0.00	50.00
Increased Cort. Macrophag.	1	0.05	0.06	1.13	0.00	20.00
Apoptosis	30	1.54	1.41	10.56	0.00	100.00
Mediastinal inflammation	8	0.41	0.23	4.12	0.00	72.73

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1989					
Cyst(s)	377	18.95	19.06	25.34	0.00	100.00
Congestion	36	1.81	2.72	12.21	0.00	100.00
Erythrophagocytosis	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	44	2.21	2.83	9.83	0.00	100.00
Histiocytosis	53	2.66	2.89	13.64	0.00	100.00
Inflammatory cell foci	1	0.05	0.06	1.14	0.00	20.00
Hemosiderosis	2	0.10	0.13	1.61	0.00	20.00
Atrophy	258	12.97	12.80	26.91	0.00	100.00
Hyperplastic epithelium	11	0.55	0.55	4.84	0.00	60.00
Increased Cort. Macrophag.	0	0.00	0.00	0.00	0.00	0.00
Apoptosis	17	0.85	0.81	7.29	0.00	100.00
Mediastinal inflammation	0	0.00	0.00	0.00	0.00	0.00

Spleen

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2066					
Malformation	0	0.00	0.00	0.00	0.00	0.00
Accessory spleen	0	0.00	0.00	0.00	0.00	0.00
Congestion	68	3.29	3.83	17.03	0.00	100.00
Erythrophagocytosis	1	0.05	0.06	1.11	0.00	20.00
Erythropoiesis	73	3.53	3.09	16.30	0.00	100.00
Granulopoiesis	0	0.00	0.00	0.00	0.00	0.00
Hemopoiesis	1260	60.99	61.90	40.57	0.00	100.00
Megakaryocytosis	9	0.44	0.55	6.54	0.00	100.00
Hemosiderin	479	23.18	20.14	33.21	0.00	100.00
Pigment deposition	1	0.05	0.03	0.55	0.00	10.00
Lymphoid atrophy	2	0.10	0.09	1.24	0.00	20.00
Atrophy	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	25	1.21	1.46	7.65	0.00	80.00
Lymphoid depletion	1	0.05	0.03	0.55	0.00	10.00
Plasmacytosis	1	0.05	0.03	0.55	0.00	10.00
Histiocytosis	1	0.05	0.03	0.55	0.00	10.00
Granulocytic infiltration	3	0.15	0.18	2.47	0.00	40.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2088					
Malformation	1	0.05	0.06	1.11	0.00	20.00
Accessory spleen	1	0.05	0.06	1.11	0.00	20.00
Congestion	84	4.02	4.75	17.64	0.00	100.00
Erythrophagocytosis	0	0.00	0.00	0.00	0.00	0.00
Erythropoiesis	60	2.87	2.69	15.36	0.00	100.00
Granulopoiesis	1	0.05	0.06	1.11	0.00	20.00
Hemopoiesis	1205	57.71	60.28	40.18	0.00	100.00
Megakaryocytosis	15	0.72	0.84	8.24	0.00	100.00
Hemosiderin	845	40.47	40.00	43.91	0.00	200.00
Pigment deposition	19	0.91	1.18	10.57	0.00	100.00
Lymphoid atrophy	0	0.00	0.00	0.00	0.00	0.00
Atrophy	4	0.19	0.12	2.23	0.00	40.00
Lymphoid hyperplasia	24	1.15	1.42	7.47	0.00	60.00
Lymphoid depletion	1	0.05	0.06	1.11	0.00	20.00
Plasmacytosis	0	0.00	0.00	0.00	0.00	0.00
Histiocytosis	0	0.00	0.00	0.00	0.00	0.00
Granulocytic infiltration	2	0.10	0.12	2.23	0.00	40.00

Joint

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	505					
Mononuclear cell infiltration	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell infiltration	0	0.00	0.00	0.00	0.00	0.00
Synovitis	2	0.40	0.23	1.98	0.00	16.67
Inflammation ligament, insertion	1	0.20	1.41	11.87	0.00	100.00
Cartilage degeneration	0	0.00	0.00	0.00	0.00	0.00
Fracture	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	505					
Mononuclear cell infiltration	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell infiltration	1	0.20	0.14	1.19	0.00	10.00
Synovitis	1	0.20	0.28	2.37	0.00	20.00
Inflammation ligament, insertion	1	0.20	0.28	2.37	0.00	20.00
Cartilage degeneration	1	0.20	0.28	2.37	0.00	20.00
Fracture	0	0.00	0.00	0.00	0.00	0.00

Bone

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	608					
Chondromucinous degeneration	80	13.16	2.03	10.55	0.00	70.00
Increased bone density	0	0.00	0.00	0.00	0.00	0.00
Disorganized physis	0	0.00	0.00	0.00	0.00	0.00
Physis hyperplasia	0	0.00	0.00	0.00	0.00	0.00
Trabecular increase	0	0.00	0.00	0.00	0.00	0.00
Remodelling increase	1	0.16	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	598					
Chondromucinous degeneration	97	16.22	2.48	11.93	0.00	83.33
Increased bone density	4	0.67	0.51	4.53	0.00	40.00
Disorganized physis	1	0.17	0.26	2.26	0.00	20.00
Physis hyperplasia	1	0.17	0.00	0.00	0.00	0.00
Trabecular increase	1	0.17	0.00	0.00	0.00	0.00
Remodelling increase	0	0.00	0.00	0.00	0.00	0.00

Skeletal muscle

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	838					
Mononuclear cell foci	27	3.22	2.58	7.25	0.00	50.00
Inflammatory cell foci	1	0.12	0.19	1.96	0.00	20.00
Myofiber degeneration	4	0.48	0.27	1.59	0.00	10.00
Myofiber regeneration	1	0.12	0.10	0.98	0.00	10.00
Degeneration	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	909					
Mononuclear cell foci	20	2.20	1.74	6.46	0.00	40.00
Inflammatory cell foci	5	0.55	0.57	3.35	0.00	20.00
Myofiber degeneration	10	1.10	0.92	4.79	0.00	40.00
Myofiber regeneration	0	0.00	0.00	0.00	0.00	0.00
Degeneration	1	0.11	0.10	0.98	0.00	10.00

Body cavities

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	4					
Cystic structure	1	25.00	33.33	57.74	0.00	100.00
Fat necrosis	1	25.00	33.33	57.74	0.00	100.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1					
Cystic structure	1	100.00	100.00	0.00	100.00	100.00
Fat necrosis	1	100.00	100.00	0.00	100.00	100.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00

Adipose tissue

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					

Injection sites

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	60					
Hemorrhage	17	28.33	24.29	31.01	0.00	90.00
Hemosiderin	1	1.67	1.43	3.78	0.00	10.00
Thrombophlebitis	3	5.00	4.29	11.34	0.00	30.00
Thrombosis	7	11.67	10.00	19.15	0.00	50.00
Intimal poliferation	20	33.33	28.57	41.00	0.00	100.00
Phelbitis	7	11.67	10.00	26.46	0.00	70.00
Periphelbitis	10	16.67	14.29	37.80	0.00	100.00
Perivascular fibrosis	1	1.67	1.43	3.78	0.00	10.00
Necrosis	7	11.67	10.00	26.46	0.00	70.00
Ulceration	2	3.33	2.86	7.56	0.00	20.00
Inflammation	35	58.33	50.00	48.65	0.00	100.00
Medial degeneration	0	0.00	0.00	0.00	0.00	0.00
Degeneration	8	13.33	11.43	30.24	0.00	80.00
Fibrosis	1	1.67	1.43	3.78	0.00	10.00
Myofiber degeneration/ necrosis	3	5.00	4.29	11.34	0.00	30.00
Folliculitis	4	6.67	5.71	15.12	0.00	40.00
Epidermal hyperplasia	1	1.67	1.43	3.78	0.00	10.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	50					
Hemorrhage	12	24.00	20.00	22.80	0.00	50.00
Hemosiderin	3	6.00	5.00	12.25	0.00	30.00
Thrombophlebitis	0	0.00	0.00	0.00	0.00	0.00
Thrombosis	5	10.00	8.33	9.83	0.00	20.00
Intimal poliferation	22	44.00	36.67	49.67	0.00	100.00
Phelbitis	0	0.00	0.00	0.00	0.00	0.00
Periphelbitis	0	0.00	0.00	0.00	0.00	0.00
Perivascular fibrosis	3	6.00	5.00	12.25	0.00	30.00
Necrosis	0	0.00	0.00	0.00	0.00	0.00
Ulceration	0	0.00	0.00	0.00	0.00	0.00
Inflammation	36	72.00	60.00	46.90	0.00	100.00
Medial degeneration	1	2.00	1.67	4.08	0.00	10.00
Degeneration	9	18.00	15.00	36.74	0.00	90.00
Fibrosis	2	4.00	3.33	5.16	0.00	10.00
Myofiber degeneration/ necrosis	0	0.00	0.00	0.00	0.00	0.00
Folliculitis	0	0.00	0.00	0.00	0.00	0.00
Epidermal hyperplasia	0	0.00	0.00	0.00	0.00	0.00

Injection sites- right

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Inflammatory cell infiltration	3	30.00	30.00	0.00	30.00	30.00
Subcutaneous fibrosis	3	30.00	30.00	0.00	30.00	30.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Inflammatory cell infiltration	4	40.00	40.00	0.00	40.00	40.00
Subcutaneous fibrosis	5	50.00	50.00	0.00	50.00	50.00

Injection sites- left

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Hemorrhage	1	10.00	10.00	0.00	10.00	10.00
Inflammatory infiltration	9	90.00	90.00	0.00	90.00	90.00
Subcutan fibrosis	9	90.00	90.00	0.00	90.00	90.00
Dermal inflammation	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Hemorrhage	1	10.00	10.00	0.00	10.00	10.00
Inflammatory infiltration	5	50.00	50.00	0.00	50.00	50.00
Subcutan fibrosis	7	70.00	70.00	0.00	70.00	70.00
Dermal inflammation	1	10.00	10.00	0.00	10.00	10.00

Injection site: tail

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	20					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Thrombosis	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell infiltration	0	0.00	0.00	0.00	0.00	0.00
Inflammation	2	10.00	6.67	11.55	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	20					
Hemorrhage	1	5.00	3.33	5.77	0.00	10.00
Thrombosis	2	10.00	0.00	0.00	0.00	0.00
Inflammatory cell infiltration	1	5.00	3.33	5.77	0.00	10.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Injection site: cranial

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Dermal inflammation	5	50.00	50.00	0.00	50.00	50.00
Scab / Parakeratosis	1	10.00	10.00	0.00	10.00	10.00
Folliculitis	1	10.00	10.00	0.00	10.00	10.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Dermal inflammation	5	50.00	50.00	0.00	50.00	50.00
Scab / Parakeratosis	1	10.00	10.00	0.00	10.00	10.00
Folliculitis	0	0.00	0.00	0.00	0.00	0.00

Injection site: caudal

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Scab / Parakeratosis	0	0.00	0.00	0.00	0.00	0.00
Folliculitis	1	10.00	10.00	0.00	10.00	10.00
Ulceration	1	10.00	10.00	0.00	10.00	10.00
Dermal inflammation	3	30.00	30.00	0.00	30.00	30.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Scab / Parakeratosis	0	0.00	0.00	0.00	0.00	0.00
Folliculitis	0	0.00	0.00	0.00	0.00	0.00
Ulceration	0	0.00	0.00	0.00	0.00	0.00
Dermal inflammation	4	40.00	40.00	0.00	40.00	40.00

Retroorbital tissue

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	20					
Hemorrhage	16	80.00	80.00	14.14	70.00	90.00
Inflammation	5	25.00	25.00	7.07	20.00	30.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	20					
Hemorrhage	11	55.00	55.00	7.07	50.00	60.00
Inflammation	9	45.00	45.00	7.07	40.00	50.00

Treated skin

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	65					
Hemorrhage	1	1.54	1.25	3.54	0.00	10.00
Scab formation	1	1.54	2.50	7.07	0.00	20.00
Inflammatory cell infiltration	4	6.15	6.25	9.16	0.00	20.00
Folliculitis	1	1.54	1.25	3.54	0.00	10.00
Inflammation	2	3.08	5.00	9.26	0.00	20.00
Acanthosis	15	23.08	25.00	46.29	0.00	100.00
Hyperkeratosis	15	23.08	25.00	46.29	0.00	100.00
Epithelial hyperplasia	1	1.54	2.50	7.07	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	65					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Scab formation	1	1.54	1.25	3.54	0.00	10.00
Inflammatory cell infiltration	0	0.00	0.00	0.00	0.00	0.00
Folliculitis	0	0.00	0.00	0.00	0.00	0.00
Inflammation	3	4.62	7.50	10.35	0.00	20.00
Acanthosis	7	10.77	13.75	28.75	0.00	80.00
Hyperkeratosis	8	12.31	16.25	35.43	0.00	100.00
Epithelial hyperplasia	0	0.00	0.00	0.00	0.00	0.00

Untreated skin

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	50					
Inflammatory cell foci	2	4.00	3.33	8.16	0.00	20.00
Scab	0	0.00	0.00	0.00	0.00	0.00
Hair follicle atrophy	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	50					
Inflammatory cell foci	0	0.00	0.00	0.00	0.00	0.00
Scab	1	2.00	1.67	4.08	0.00	10.00
Hair follicle atrophy	1	2.00	1.67	4.08	0.00	10.00

Skin non-rout untraeted

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	2					
Dermatitis	0	0.00	0.00	0.00	0.00	0.00
Hair follicle atrophy	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	9					
Dermatitis	1	11.11	11.11	0.00	11.11	11.11
Hair follicle atrophy	2	22.22	22.22	0.00	22.22	22.22

Skin sample 1

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Mononuclear cell foci	1	10.00	10.00	0.00	10.00	10.00
Follicular degeneration	1	10.00	10.00	0.00	10.00	10.00
Epidermal hyperplasia	1	10.00	10.00	0.00	10.00	10.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Mononuclear cell foci	1	10.00	10.00	0.00	10.00	10.00
Follicular degeneration	0	0.00	0.00	0.00	0.00	0.00
Epidermal hyperplasia	0	0.00	0.00	0.00	0.00	0.00

Skin sample 2

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Mononuclear cell foci	3	30.00	30.00	0.00	30.00	30.00
Scab	1	10.00	10.00	0.00	10.00	10.00
Epidermal vacuolation	1	10.00	10.00	0.00	10.00	10.00
Epidermal hyperplasia	3	30.00	30.00	0.00	30.00	30.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Mononuclear cell foci	2	20.00	20.00	0.00	20.00	20.00
Scab	1	10.00	10.00	0.00	10.00	10.00
Epidermal vacuolation	0	0.00	0.00	0.00	0.00	0.00
Epidermal hyperplasia	3	30.00	30.00	0.00	30.00	30.00

Ears

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	16					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	16					

Tail

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Thrombus	0	0.00	0.00	0.00	0.00	0.00
Vasculitis	0	0.00	0.00	0.00	0.00	0.00
Fibrinoid necrosis	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Hemorrhage	2	20.00	20.00	0.00	20.00	20.00
Thrombus	1	10.00	10.00	0.00	10.00	10.00
Vasculitis	3	30.00	30.00	0.00	30.00	30.00
Fibrinoid necrosis	1	10.00	10.00	0.00	10.00	10.00

Infusion site

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	38					
Necrosis	32	84.21	84.21	0.00	84.21	84.21
Periphlebitis	24	63.16	63.16	0.00	63.16	63.16
Thrombophlebitis	1	2.63	2.63	0.00	2.63	2.63
Phlebitis	3	7.89	7.89	0.00	7.89	7.89
Inflammation	7	18.42	18.42	0.00	18.42	18.42

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	0					
Necrosis	0	0.00	0.00	0.00	0.00	0.00
Vascular fibrosis	0	0.00	0.00	0.00	0.00	0.00
Periphlebitis	0	0.00	0.00	0.00	0.00	0.00
Thrombophlebitis	0	0.00	0.00	0.00	0.00	0.00
Phlebitis	0	0.00	0.00	0.00	0.00	0.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00